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Centrosomal abnormalities, in particular centrosome
amplification, are recurrent features of human tumors.
Enforced centrosomeamplification in vivoplays a role
in tumor initiation and progression. However, centro-
some amplification occurs only in a subset of cancer
cells, and thus, partly due to this heterogeneity, the
contribution of centrosome amplification to tumors
is unknown. Here, we show that supernumerary cen-
trosomes induce a paracrine-signaling axis via the
secretion of proteins, including interleukin-8 (IL-8),
which leads to non-cell-autonomous invasion in 3D
mammary organoids and zebrafish models. This
extra centrosomes-associated secretory phenotype
(ECASP) promotes invasion of humanmammary cells
via HER2 signaling activation. Further, we demon-
strate that centrosome amplification induces an early
oxidative stress response via increased NOX-gener-
ated reactive oxygen species (ROS), which in turn
mediates secretion of pro-invasive factors. The dis-
covery that cells with extra centrosomes canmanipu-
late the surrounding cells highlights unexpected and
far-reaching consequences of these abnormalities in
cancer.
INTRODUCTION
The centrosome is the principal microtubule (MT) organizing
center in animal cells and consists of a pair of centrioles sur-
rounded by the pericentriolar material (PCM) (Bettencourt-Dias
and Glover, 2007). The centrosome is duplicated once per cell
cycle during S-phase to ensure that at the onset of mitosis,
cells have two centrosomes. The importance of the centrosome
cycle is emphasized by its tight regulation and conservation
throughout evolution (Nigg and Stearns, 2011; Werner et al.,
2017). However, cancer cells often display centrosomal abnor-
malities; in particular, centrosome amplification has been exten-
sively characterized in both solid and hematological malig-
nancies (Chan, 2011; Marteil et al., 2018; Zyss and Gergely,
2009). Mounting evidence indicates that extra centrosomes areDevelopmental Cell 47, 409–424, Nove
This is an open access article undnot bystanders of tumor progression and can directly impact
tumorigenesis by generating aneuploidy and promoting the
acquisition of invasive traits (Ganem et al., 2009; Godinho
et al., 2014). Furthermore, recently developed mouse models
demonstrated that induction of centrosome amplification, via
transient Polo-like kinase 4 (PLK4) overexpression, not only
accelerates tumorigenesis in the absence of the tumor suppres-
sor p53 (Coelho et al., 2015; Sercin et al., 2016) but also pro-
motes tumor formation in p53-proficient mice (Levine et al.,
2017). Therefore, centrosome amplification can play a role in
the initiation and progression of tumors.
Intriguingly, the presence of supernumerary centrosomes
comes with a cost (Rhys and Godinho, 2017). Cells with extra
centrosomes divide slower and require efficient mechanisms
that enable the formation of a ‘‘pseudo-bipolar’’ spindle during
mitosis (e.g., centrosome clustering) to prevent catastrophic
multipolar division (Basto et al., 2008; Ganem et al., 2009;
Kwon et al., 2008; Rhys et al., 2018). Furthermore, in cells
with intact tumor suppressors, centrosome amplification in-
duces p53-mediated cell-cycle arrest (Fava et al., 2017;
Holland et al., 2012). Thus, while it is predictable that cells
with extra centrosomes undergo negative selection in vitro
(Krzywicka-Racka and Sluder, 2011; Mittal et al., 2017), it is
perhaps counterintuitive that in vivo tumors maintain ‘‘less-fit’’
cells carrying centrosomal abnormalities. This is particularly
surprising given tumor heterogeneity, where most human
tumors display high genetic and phenotypic diversity (McGra-
nahan and Swanton, 2017), including heterogeneous centro-
some numbers (Chan, 2011). Thus, why are cells with extra
centrosomes not outcompeted during tumor evolution? It is
becoming clear that tumor evolution cannot be merely ex-
plained by positive selection of the fittest clones (McGranahan
and Swanton, 2017; Tabassum and Polyak, 2015). In fact, wide-
spread intratumor heterogeneity (ITH) challenges the idea that
the dominant subclone solely drives tumor phenotypes in a
cell autonomous manner (McGranahan and Swanton, 2017).
Using mouse xenograft models, Polyak and colleagues found
that a subclone overexpressing interleukin (IL)-11 acted as a
non-cell-autonomous driver of tumor growth and was essential
to maintain ITH by promoting the growth of less-fit clones
(Marusyk et al., 2014). Here, we set out to investigate whether
cells with extra centrosomes play non-cell-autonomous roles
that could benefit the surrounding cells and explain their main-
tenance in tumors.mber 19, 2018 ª 2018 The Authors. Published by Elsevier Inc. 409
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
Centrosome Amplification Induces Paracrine Invasion
To investigate whether the presence of extra centrosomes pro-
motes non-cell-autonomous functions, we took advantage of
non-transformed cells to avoid additional effects caused by can-
cer mutations. To do so, conditioned media (CM) was collected
from our previously established human mammary epithelial cell
line MCF10A.PLK4 (donor [D] cells) where centrosome amplifi-
cation is driven by transient induction of PLK4 upon doxycycline
(DOX) treatment (Godinho et al., 2014) (Figure S1A). CM
collected at 16, 24, and 36 hr from donor cells was added on
top of recipient (R) MCF10A cells grown in 3D cultures, which
form acinar structures (Figure 1A). Strikingly, CM collected
from cells with extra centrosomes (CM+DOX) was able to
induce a robust invasive phenotype (20%), characterized by
the formation of actin-rich invasive protrusions capable of de-
grading the basement membrane (Figures 1B and S1B). We pre-
viously found that centrosome amplification was sufficient to
drive invasion in a cell-autonomous manner (Godinho et al.,
2014); however, paracrine invasion was not a consequence of
increased centrosome numbers in the recipient cells (Fig-
ure S1A). Live cell imaging of 3D acini treated with CM shows
how these invasive protrusions enable collective migration
through the extracellular matrix (ECM) (Videos S1 and S2) and
allow cells to invade the surrounding environment (Figure S1C;
Videos S3 and S4). When compared with invasive protrusions
induced directly by extra centrosomes, protrusions induced by
the CM+DOX appeared morphologically distinct, containing
increased percentages of nuclei (23% as opposed to 5%)
(Figure S1D). Moreover, when added on top of cells with extra
centrosomes (+DOX), CM+DOX further increased invasion,
with many of the structures displaying a more severe and
abnormal invasive phenotype (Figure S1E), suggesting an addi-
tive effect. CM collected from human keratinocytes with extra
centrosomes (HaCat.PLK4+DOX) also induced paracrine inva-
sion of MCF10A cells, showing that this phenotype is not cell-
type dependent (Figure S1F and Table S1).
We established that secretion of pro-invasive factors is a
direct consequence of centrosome amplification and not due
to unspecific effects of PLK4 overexpression or DOX treatment.
First, depletion of SAS-6, a centrosomal protein essential for
centrosome duplication (Rodrigues-Martins et al., 2007; Strnad
et al., 2007), in cells upon overexpression of PLK4 (+DOX) pre-
vents centrosome amplification and paracrine invasion (Figures
1C and 1D). Second, CM collected from cells treated with
DOX to induce the expression of a truncated PLK4 mutant
(PLK41–608) that does not induce centrosome amplification
does not induce paracrine invasion (Figure 1E) (Guderian et al.,
2010). Third, depletion of SAS-6 after centrosome amplification
leads to loss of extra centrosomes and blocks the ability of these
cells to induce paracrine invasion, demonstrating that this
phenotype can be reversed by loss of extra centrosomes (Fig-
ures S1G and S1H; Table S1). Finally, increased paracrine inva-
sion was observed in cells where centrosome amplification was
generated by prolonged CDK1 inhibition, in the absence of DOX
treatment (Figure S1I and Table S1) (Loncarek et al., 2010).
We validated the ability of cells with extra centrosome to pro-
mote paracrine invasion in primary mouse mammary organoids410 Developmental Cell 47, 409–424, November 19, 2018that better recapitulate the architecture of the mammary gland.
In this system, both myoepithelial cells (expressing a-SMA)
and luminal cells become invasive upon treatment with CM
from cells with extra centrosomes (Figures 1F and 1G). This
type of invasion, in particular the collective invasive strands, re-
sembles what has been described for invasive tumor organoids
in 3D cultures (Cheung et al., 2013). Branching morphogenesis
can also be observed in these conditions, but we did not quantify
this phenotype as invasion (Figure S1J).
To test if in the context of heterogeneous cell populations,
cells with extra centrosomes could promote invasion of sur-
rounding cells, we took advantage of the zebrafish model where
co-injection of differentially labeled cells was performed. While
injection of MCF10A cells with normal centrosome number
(DOX) does not induce an invasive phenotype, induction of
centrosome amplification (+DOX) is sufficient to promote an
invasive behavior in vivo, scored as the percentage of fish with
cells that invaded into the tail (20%) (Figures 1H–1J). However,
when control cells and cells with extra centrosomes are
co-injected, non-invasive control cells become invasive (15%)
(Figures 1H–1J). These results support a non-cell-autonomous
role for centrosome amplification in vivo.
Induction of Paracrine Invasion Is Mediated by RTK
Signaling
To investigate the mechanisms by which CM from cells with ex-
tra centrosomes promoted invasion, we first tested if CM+DOX
induced epithelial to mesenchymal transition (EMT) in MCF10A
cells. We found that cells treated with CM+DOX did not undergo
EMT, as assessed by the expression of epithelial (E-cadherin)
and mesenchymal (N-cadherin and Vimentin) markers (Fig-
ure S2A). Next, we tested if the pro-invasive factors secreted
by cells with extra centrosomes were permanently making
them invasive by pre-treating MCF10A cells with CM for 48 hr
before plating in 3D cultures (CM OFF) (Figure 2A). We
found that pre-treatment with CM+DOX was not sufficient to
induce an invasive phenotype (Figure 2A). Thus, signaling
activation via secreted molecules is likely inducing paracrine in-
vasion. To uncover the origin of the secreted pro-invasive
factors, we filtered the CM using Vivaspin columns with a
5 kDa cutoff to separate larger molecules (e.g., proteins) from
small molecules (e.g., metabolites). We found that only the larger
fraction (>5 kDa) was able to induce invasion (Figures S2B and
S2C). Treatment of the CM+DOX with trypsin-coated beads
completely abolished the invasive phenotype, further supporting
that it is a protein-mediated phenotype (Figures 2B and S2B).
To dissect the signaling pathways activated by CM+DOX, we
performed a phospho-receptor tyrosine kinase (RTK) array in
MCF10A cells treatedwith CMcollected from control (CMDOX)
and cells with extra centrosomes (CM+DOX). Analyses of the
phospho-RTK array revealed that EGFR, HER2 (ErbB2), and
c-Met (HGFR) signaling were increased in cells treated with
CM+DOX, although only HER2 was significantly increased (Fig-
ures 2C and S2D). Addition of the HER2 inhibitor (Trastuzumab),
but not the c-Met inhibitor (PHA-66752) to the recipient cells,
prevented paracrine invasion induced by the CM+DOX, without
affecting acinar growth (Figures 2D, S2E, and S2F). Our data
demonstrate that activation of HER2 signaling in the recipient
cells drives non-cell-autonomous invasion. Because EGF
Figure 1. Centrosome Amplification Induces Paracrine Invasion
(A) Experimental flowchart.
(B) Left, quantification of invasive structures. Right, normal and invasive 3D acini. White arrowheads indicate invasive protrusions. Scale bar: 20 mM.
(C) Quantification of centrosome amplification.
(D) Quantification of invasive structures.
(E) Quantification of invasive structures.
(F) Top, schematic representation of mammary organoids isolation and growth. Bottom, non-invasive and invasive mammary organoids. Scale bar: 20 mM.
(G) Quantification of invasive organoids.
(H) Images of zebrafish injected with cells with (+DOX) or without (DOX) extra centrosomes (left) or co-injected +DOX/DOX (right).
(I) Incidence of invasive cells in zebrafish embryos. Number of injected fish DOX = 121; +DOX = 103; and co-injection +/DOX = 116.
(J) Number of disseminated cells in the zebrafish tail. Error bars represent mean ± SEM.
For all graphics, error bars represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns not significant.
See also Figure S1; Videos S1, S2, S3, and S4; Table S1.
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Figure 2. Induction of Paracrine Invasion Is
Mediated by RTK Signaling
(A) Left, schematic representation of the different
CM treatments. Right, quantification of invasive
structures.
(B) Quantification of invasive structures.
(C) Fold increase in RTK phosphorylation in
MCF10A cells after incubation with CM+DOX.
(D) Left, quantification of invasive structures with or
without HER2 (Trastuzumab, 40 mg/mL) and c-Met
(PHA-66752, 1 mM) inhibitors. Right, acinar struc-
tures. Red arrowheads indicate invasive acini.
Scale bar: 40 mM.
For all graphics, error bars represent mean ± SD
from three independent experiments. **p < 0.01,
***p < 0.001, ****p < 0.0001; ns not significant.
See also Figure S2.signaling is essential for MCF10A proliferation, it remains unde-
termined if EGFR is important for the invasive phenotype
observed (Figures S2G and S2H).
Secretome Analysis Reveals Differential Protein
Secretion in Cells with Amplified Centrosomes
To identify the secretedproteins important for paracrine invasion,
we performed label-free mass spectrometry on the CMDOX
and CM+DOX (Figure 3A). CM was collected 16 hr after incuba-
tion with serum-free medium to prevent cell death, as assessed
by the presence of the enzyme lactate dehydrogenase (LDH) in
the media (Figure S2I). Proteomic analyses uncovered changes
(log2-fold > 1.5) in the secretomes of cells with and without
centrosome amplification (Figure 3B and Table S2), demon-
strating theexistence of anextra centrosomes-associated secre-
tory phenotype (ECASP). Similar to other secretomic studies
(Acosta et al., 2013), qualification of proteins differentially present
in theCM revealed that approximately 25%of those are assigned
to the extracellular compartment (Figure 3C). Further analyses of
this compartment suggested that many of the identified secreted
proteins have been previously associated with extracellular ves-
icles, particularly exosomes (Exos) (Figure 3C). However, while
fractions enriched for microvesicles (MVs) or Exos did not signif-
icantly promote invasion, CM depleted of extracellular vesicles
(MVs and Exos) retained the potential to induce invasion (Fig-
ure S2J). To complement our secretomic analyses and exclude
proteins associated with MVs and Exos, we performed a quanti-
tative membrane-based protein array (Human XL Oncology
Array) of the collected CM (Figures 3A and 3D). Short and long
exposures of the membranes revealed proteins significantly
secreted by cells with amplified centrosome number (Figures
3D and S2K). Ingenuity pathway analysis (IPA) of the secreted
proteins identified by mass spectrometry and/or protein array
demonstrated that many have been previously linked to cancer412 Developmental Cell 47, 409–424, November 19, 2018invasion and migration (Figure 3E and
TableS3). From those,weselected38pro-
teins based on fold change and function
in cancer (Table S4) and performed a
small-scale small interfering RNA (siRNA)
screen in cells with extra centrosomes to
identify the secreted pro-invasive proteins(Figures S3A and S3B). qRT-PCR to assess knockdown effi-
ciency indicated that 3 out of 38 proteins were not depleted,
and therefore they were not pursued further (Figure S3C). We
identified 11 proteins that upon depletion decreased paracrine
invasion by at least 1 standard deviation (SD) of the siRNA control
condition (5%) (Figure 3F, green circles). The decrease in para-
crine invasion was independent of cell viability and proliferation
rates (Figure S3D). We further validated some of the hits that
have been previously associated with invasion using indepen-
dent siRNA pool sets: Interleukin-8 (IL-8), Mesothelin (MSLN),
Angiopoietin-like protein 4 (ANGPTL4), SerpinE1 (PAI), and
Growth-Factor Differentiation 15 (GDF-15) (Figures 3G and
S3E) and confirmed their increased secretion by ELISA (Figures
S4A–S4E). Apart from GDF-15, increased secretion of these fac-
tors at 48 hr cannot be explained by increasedmRNA levels (Fig-
ure S4F). One of our top hits, IL-8, also known as C-X-C motif
ligand 8 (CXCL8), is a pro-inflammatory chemokine with known
roles in promoting cancer cell invasion (Waugh and Wilson,
2008). IL-8 signaling has also been shown to induce transactiva-
tion of HER2 (Singh et al., 2013), which is important for centro-
some amplification-induced paracrine invasion (Figure 2D).
Deconvoluted siRNA pools for IL-8 confirmed its role in paracrine
invasion (Figure S4G). Furthermore, while recombinant IL-8 was
not sufficient to induce invasion when added to CMDOX, it fully
restored the invasive capacity of the CM+DOX collected from
cells depleted of IL-8 (Figures S4H and S4I). Taken together,
our data suggest that paracrine invasion inducedby extra centro-
somes is likely promoted by a combination of secreted factors,
with IL-8 playing a crucial role.
Secreted IL-8 Is Crucial for Paracrine Invasion through
HER2 Activation
To investigate the mechanisms by which IL-8 could be promoting
paracrine invasion, we inhibited IL-8G-protein-coupled receptors
Figure 3. Secretome Analysis Reveals Differential Protein Secretion in Cells with Amplified Centrosomes
(A) Experimental flowchart.
(B) Log2-fold changes in protein abundance in the CM of cells with extra centrosomes (+DOX). Red circles indicate changes >1.5-fold difference.
(C) Pie charts represent the cellular localization of the proteins increased in CM+DOX. See STAR Methods for details.
(D) Fold change of secreted proteins in CM+DOX using protein array.
(E) IPA classification of the extracellular secreted proteins identified by mass spectrometry and protein arrays.
(F) Quantification of invasive structures after siRNA depletion.
(G) Left, validation of specific positive hits identified in (F). Right, acinar structures. Red arrowheads indicate invasive acini. For all graphics, error bars represent
mean ± SD from three independent experiments. *p < 0.05, **p < 0.01. Scale bar: 40 mM.
See also Figure S3 and Table S1.CXCR1 and CXCR2 in the recipient cells using specific inhibitors
(Casilli et al., 2005; Chao et al., 2007). While the CXCR1/2 allo-
steric inhibitor Reparixin only partially prevented invasion, inhibi-
tion of CXCR1/2 with SCH563705 (potently inhibits CXCR2) abol-
ished paracrine invasion without affecting 3D growth (Figure 4A).
This was confirmed by siRNA depletion of CXCR2 in the recipient
cells (Figures 4B and 4C). Importantly, CXCR2 depletion in cellswith extra centrosomes did not prevent direct invasion, although
we did observe a consistent decrease in the invasive phenotype
(Figure 4C). These results further support that the pathways that
underline direct and paracrine invasion are distinct.We confirmed
the importance of IL-8 signaling in this process using mouse
mammary organoids. Althoughmice do not express IL-8, they ex-
press CXCR2 that binds to human IL-8 (Singer and Sansonetti,Developmental Cell 47, 409–424, November 19, 2018 413
Figure 4. Secreted IL-8 Is Crucial for Paracrine Invasion through Her2 Activation
(A) Left, quantification of invasive structures with and without the CXCR1/2 inhibitors Reparixin (100 nM) and SCH563705 (100 nM). Right, acinar structures. Red
arrowheads indicate invasive acini. Scale bar: 40 mM.
(B) Experimental flowchart.
(C) Quantification of invasive structures upon CXCR2 depletion in cells with extra centrosomes (direct) or incubated with CM+DOX (paracrine).
(D) Left, quantification of invasive mammary organoids from WT or CXCR2/ mice. Right, non-invasive and invasive mammary organoids. Scale bar: 20 mM.
(E) Left, ratio of disseminated cells in co-injection experiments. Right, zebrafish embryos co-injected with cells with (+DOX, red) and without centrosome
amplification (DOX, green). Number of injected fish co-injection control siRNA = 71; co-injection CXCR2 siRNA = 121.
(F) Top, levels of p-Erk1/2 and total Erk1/2 in cells. Bottom, ratio of phospho/total Erk1/2. B, basal conditions; S, serum starved cells; +M, serum starved cells after
incubation with fresh medium.
(G) Left, quantification of invasive structures with or without Erk1/2 inhibitor (PD98059, 20 mM). Right, acinar structures. Red arrowheads indicate invasive
acini. Scale bar: 40 mM.
(legend continued on next page)
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2004). Mammary organoids generated from mice knockout for
CXCR2 (CXCR2/) did not show increased invasion when
treated with CM+DOX (Figures 4D and S4J). Co-injection experi-
ments in zebrafish demonstrated that, although depletion of
CXCR2 in control MCF10A cells (DOX) did not abolish paracrine
invasion (Figure S4K), it significantly decreased the number of
control cells that co-invaded with cells with extra centrosomes
(+DOX), indicating that IL-8 signaling plays an important role in
paracrine invasion in vivo (Figure 4E).
Because CM+DOX activates HER2 (Figure 2C), we decided to
test if HER2 activation requires IL-8 signaling. To do so, we as-
sessed Erk1/2 phosphorylation, as a consequence of HER2
activation, in recipient cells treated with CM+DOX. We found
that, when compared to CMDOX, CM+DOX induces a 2-fold
increase in Erk1/2 activation. Moreover, pre-treating the
recipient cells with HER2 or CXCR1/2 inhibitors significantly
decreased Erk1/2 activation (Figure 4F). Similar to HER2 inhibi-
tion, chemical inhibition of Erk1/2 and Src, important for HER2
transactivation mediated by IL-8 (Singh et al., 2013), in the recip-
ient cells also prevented invasion induced by CM+DOX (Figures
4G and 4H). Taken together, our results show that Erk1/2 activa-
tion is important for paracrine invasion and requires activation of
the IL-8 receptor.
Centrosome Amplification Induces an Early Stress
Response that Leads to Altered Secretion
Altered protein secretion in senescent cells, known as the senes-
cence-associated secretory phenotype (SASP), was previously
shown to lead to IL-8 secretion (Coppe et al., 2008). Early secre-
tory phenotype observed in cells with extra centrosomes is
unlikely to be a consequence of senescence since it is induced
very early (48 hr after induction of extra centrosomes), and
high levels of proliferating cells can be observed even after
6 days, as measured by ki67 staining (Figure 5A). However, the
percentage of dividing cells with extra centrosomes is lower at
day 6 (Table S1). Thus, it is possible that this early response to
centrosome amplification could culminate in a senescence
phenotype. To test this idea, we performed b-galactosidase
staining in cells 6 and 10 days after induction of centrosome
amplification. In contrast to cells treated with the DNA-dam-
age-inducing drug Doxorubicin (DoxoR) (Bolesta et al., 2012),
centrosome amplification in MCF10A cells was not sufficient to
drive a strong senescence phenotype (Figures 5B and S5A).
However, our data suggest that these cells display senes-
cence-like features. First, centrosome amplification increases
p53 and p21 protein levels (Holland et al., 2012) (Figure S5B),
which is also observed in senescent cells (Wiley and Campisi,
2016). Second, the comparison of the mRNA levels of the iden-
tified pro-invasive factors at day 6 revealed a similar trend
between senescent cells (DoxoR treated) and cells with extra
centrosomes, although overall senescent cells exhibit a stronger
response (Figure S5C). In addition, senescent cells exhibit a
similar paracrine invasive behavior as centrosome amplification,(H) Left, quantification of invasive structures with andwithout Src inhibitor (PP2, 5 m
40 mM.
For all graphics, error bars represent mean ± SD from three independent experim
See also Figure S4.although they exhibit higher levels of secreted pro-invasive fac-
tors (Figures 5C, 5D, and S5G). This partial senescence-like
response could be a consequence of the lack of p16 in
MCF10A cells (Brenner and Aldaz, 1995), since both p16 and
p53 are important mediators of senescence (Wiley and Campisi,
2016). To test if centrosome amplification was sufficient to
induce senescence in cells with intact p16 and p53, we used
human retinal pigment epithelium (RPE-1) and human primary
breast fibroblast (BF) cell lines. Although RPE-1 were negative
for b-galactosidase staining, centrosome amplification was suf-
ficient to induce an enlarged cell morphology phenotype in
30% of the cells consistent with senescence after 7 days (Fig-
ure 5E and Table S1). Similar results were observed in BF cells as
scored by b-galactosidase staining (Figure S5D and Table S1).
Notably, the levels of b-galactosidase were lower than that of
BF cells treated with DoxoR, suggesting that extra centrosomes
might elicit a different or less strong senescent response.
We also assessed double-stranded DNA (dsDNA) breaks, as
measured by gH2AX foci, and found that while there is a signifi-
cant increase in cells with extra centrosomes, only 1.7% and
11.3% of MCF10A and RPE-1 cells, respectively, show more
than 5 DNA damage foci (Figure 5F). This contrasts with
DoxoR-induced senescent cells where 99% of cells have
more than 5 DNA damage foci (Figure 5F). Furthermore, while
enlarged nuclei in senescent cells induced by DoxoR correlate
with increased DNA damage foci, the same was not observed
in cells with extra centrosomes (Figures S5E and S5F). To further
understand the association of ECASP with senescence, we
compared the secretion of well-established SASP components
(Coppe et al., 2008), including IL-8 (our positive control), IL-6,
uPar, MIP-3a, MCP-1, GRO -a, -b, -c, and IL-1b, in cells with ex-
tra centrosomes or treated with DoxoR over time (48 hr and
7 days). At 48 hr, we did not observe a strong SASP, and only
secretion of IL-6 and IL-8 was observed (Figures 5G and 5H).
At 7 days, DoxoR-induced senescent cells displayed a stronger
SASP than cells with extra centrosomes in both MCF10A and
RPE-1 cells (Figures 5G and 5H). In RPE-1 cells, centrosome
amplification and DoxoR-treated cells show a similar pattern of
secreted SASP components. By contrast, MCF10A cells with ex-
tra centrosomes only show increased secretion of IL-6 and IL-8
even after 7 days (Figures 5G, 5H, and S5H). Taken together,
these results suggest that centrosome amplification can pro-
mote senescence and SASP in some cells. Similar results on a
SASP induced by centrosome amplification have also been
observed by others (D. Pellman, personal communication).
Importantly, the early secretory phenotype we observed at
48 hr does not require cells to become senescent, as these still
display high levels of proliferation. Instead, we hypothesized
that this early secretory phenotype is caused by an early stress
response, which could lead to senescence. Further supporting
this idea, secretion of HMGB1, which is secreted very early after
a senescence-induced stimulus and before the development
of SASP (Davalos et al., 2013), is also observed 48 hr afterM). Right, acinar structures. Red arrowheads indicate invasive acini. Scale bar:
ents. *p < 0.05, **p < 0.01, ***p < 0.001; ns not significant.
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Figure 5. Centrosome Amplification Induces an Early Stress Response that Leads to Altered Secretion
(A) Left, quantification of Ki67 positive cells. Right, cells stained for Ki67. Scale bar: 40 mM.
(B) Left, cells stained for b-galactosidase (blue). Right, quantification of b-galactosidase positive cells after 6 days. Scale bar: 40 mM.
(legend continued on next page)
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induction of extra centrosomes (Figure 5I). This stress response
requires p53, since short-term depletion of p53 abolished para-
crine invasion and decreased IL-8 secretion (Figures 5J, 5K, and
S5I). This is not due to cell-cycle arrest mediated by p53 since
p21 depletion did not prevent IL-8 secretion and paracrine inva-
sion (Figures S5J–S5L). Taken together, our results suggest that
a stress response downstream of extra centrosomes alters
secretion that in some conditions can develop into a SASP.
Increased ROS Levels in Cells with Extra Centrosomes
Drive Secretion
Recent work showed that induction of highly abnormal karyo-
types leads to senescence and secretion of pro-inflammatory cy-
tokines (Santaguida et al., 2017). In our conditions, induction of
centrosome amplification for 48 hr leads to low levels of chromo-
somemissegregation (Godinho et al., 2014).We found that deple-
tion of MCAK, which induces similar levels of aneuploidy to
centrosome amplification (Godinho et al., 2014), does not lead
to paracrine invasion and IL-8 secretion (Figures S5M–S5O).
One common denominator between IL-8 secretion and senes-
cence is increased reactive oxygen species (ROS) levels (Fialkow
et al., 2007; Gorrini et al., 2013). The levels of ROS can dictate the
cellular response: high levels lead to senescence and apoptosis,
whereas milder levels are associated with tumorigenesis (Gorrini
et al., 2013). Thus, we postulated that increased levels of ROS in
cells with extra centrosomes could alter secretion and, depend-
ing on the cellular context, also induce senescence. To test
this, we measured ROS levels in cells with extra centrosomes
using the fluorogenic dye DCFDA. We found that induction of
centrosome amplification induces a 1.5-fold increase in ROS,
which can be prevented by treating cells with the antioxidant
N-acetyl cysteine (NAC). A similar responsewas observed in cells
treatedwith DoxoR for 3 hr (Figure 6A). Thiswas further confirmed
by quantifying the levels of reduced Glutathione, which
is decreased in response to ROS (2-fold) (Figure 6B). Induction
of extra centrosomes leads to the nuclear accumulation of the
nuclear factor erythroid 2-related factor 2 (NRF2), a transcription
factor that is stabilized and translocates into the nucleus in
response to ROS (Figure 6C) (Gorrini et al., 2013). Consistently,
gene expression analysis of MCF10A.PLK4 with extra centro-
somes revealed an early transcriptional response involving the
overexpression of genes that control intracellular ROS, some of
which are downstream of NRF2 (Figure 6D and Table S5).
We uncovered that ROS is a key player in the paracrine inva-
sive phenotype mediated by extra centrosomes. Treatment of
cells with NAC prevented both IL-8 secretion and paracrine inva-(C) Relative IL-8 secretion (fold, ng/cell) in cells with extra centrosomes (Left) or
(D) Quantification of invasive structures.
(E) Left, cells stained for b-galactosidase (blue). Right, quantification of senesc
morphology (purple arrowheads). Scale bar: 40 mM.
(F) Left, quantification of gH2AX foci. Right, cells were stained for gH2AX. L, la
RPE-1.PLK4 DOX = 155; +DOX = 115; +DoxoR = 84. Scale bar: 20 mM.
(G and H) (G) Fold change of secreted SASP components in MCF10A and (H) RP
(I) HMGB1 secretion after 48 hr.
(J) IL-8 secretion after p53 depletion (48 hr).
(K) Quantification of invasive structures.
Graphic in (G) represents 4 independent experiments; for all other graphics, erro
**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant.
See also Figure S5 and Table S1.sion, without affecting the levels of centrosome amplification
(Figures 6E and 6F; Table S1). To test whether the lack of a clas-
sical senescent phenotype in MCF10A cells could be overcome
by further increasing ROS, we treated cells with different doses
of the ROS-inducing agent H2O2. Indeed, H2O2 concentrations
that did not induce senescence in control cells were able to
induce a stronger p53 response and promote senescence in
cells with extra centrosomes (Figures 6G and S6A–S6C). This
is consistent with increased DNA damage foci and a decrease
in cell proliferation and dividing cells with extra centrosomes
(Figures 6H, S6D, and S6E; Table S1). Moreover, 100 mM
H2O2 was sufficient to promote IL-8 secretion and paracrine in-
vasion, further supporting a role for ROS in this process (Figures
S6F and S6G). Interestingly, reducing ROS levels with NAC also
affected the secretion of ANGPTL4, GDF-15, and PAI, while
MSN was still secreted at similar levels (Figures S6H–S6K).
Because NAC prevents paracrine invasion, we tested if a combi-
nation of ROS-mediated secreted factors was sufficient to
drive invasion. In contrast to the addition of recombinant IL-8,
ANGPTL4, or GDF-15 alone, the combination of these three fac-
tors to CMDOX was sufficient to promote paracrine invasion
(Figure 6I), suggesting that ROS-mediated secretion plays
crucial roles in non-cell-autonomous invasion.
Intracellular ROS can originate in the cytoplasm or mitochon-
dria (Block and Gorin, 2012; Murphy, 2009). Inhibition of NADPH
oxidases (NOXs), which drives cytoplasmic ROS, with apocynin
decreased ROS levels, prevented IL-8 secretion and paracrine
invasion in cells with extra centrosomes (Figures 6J–6L). This
was confirmed by siRNA depletion of p22phox, a common sub-
unit of the NOX1-4 complexes (Figure S7A). By contrast, inhibi-
tion of mitochondrial ROS with MitoTempo did not prevent
paracrine invasion, and centrosome amplification did not in-
crease mitochondrial ROS, as assessed using the fluorogenic
dye MitoSox (Figures S7B–S7D).
RAC1 activity is increased in cells with extra centrosomes
(Godinho et al., 2014) and can activate NOX to increase ROS
production (Block and Gorin, 2012); therefore, we tested
whether RAC1 activity was important for ROS generation. To
do so, we used a RAC1 inhibitor that we have previously shown
to prevent increased RAC1 activity in response to centrosome
amplification (Godinho et al., 2014). In this condition, RAC1 inhi-
bition did not prevent increased ROS, and as a consequence,
these cells were able to secrete IL-8 (Figures S7E and S7F). As
RAC1 is important for the formation of invasive protrusions, we
tested if the CM+DOX collected from D cells treated with
RAC1 inhibitor still had the potential to induce invasion, aftertreated with DoxoR (Right).
ence in RPE-1.PLK4 cells. Note that senescence was assessed by enlarged
rge nuclei. Number of cells MCF10A.PLK4 DOX = 469; +DOX = 466; and
E-1 cells.
r bars represent mean ± SD from three independent experiments. *p < 0.05,
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using Vivaspin columns to remove the inhibitor from the CM
(Figure S7G). Whereas CM+DOX containing the RAC1 inhibitor
prevented the formation of invasive protrusions, after removal
of the inhibitor CM+DOX still retained the ability to induce para-
crine invasion (Figure S7H). Thus, increased RAC1 activity is not
necessary for the early secretion of pro-invasive factors.
We postulated that increased ROS could be a consequence
of p53 stabilization since p53 plays important roles in redox
homeostasis (Liu et al., 2008), and we found it to be important
for paracrine invasion (Figure 5K). The role of p53 in modulating
cellular ROS is complex. While p53 can be downstream of
high levels of ROS, p53 activation has also been shown to pro-
mote ROS, which is important to drive senescence or apoptosis
(Vigneron and Vousden, 2010). NAC treatment did not block
p53 stabilization in cells with extra centrosomes, suggesting
that p53 activation is not mediated by ROS (Figure S7I). Further-
more, we found that induction of p53 stabilization for 48 hr using
Nutlin-3, an inhibitor of the p53 negative regulator MDM2, is
sufficient to induce ROS, IL-8 secretion, and paracrine invasion
in normal MCF10A cells, independently of centrosome amplifi-
cation (Figures S7J–S7M; Table S1). Nutlin-3 treatment also
induces HMGB1 secretion, similarly to centrosome amplification
(Figure S7N). Altogether, our results suggest that p53-mediated
ROS production leads to an early secretory response in cells
with extra centrosomes that promotes non-cell-autonomous
invasion.
Centrosome Amplification in Breast Cancer Mediates
Paracrine Invasion and Is Associatedwith IL-8 Secretion
To establish the relevance of our findings in cancer, we next
tested whether CM collected from cells with supernumerary
centrosomes could induce invasion in organoid cultures of pri-
mary cells from mouse tumors derived from Polyomavirus
middle T oncogene (PyMT) (Ogura et al., 2017). We found that
CM+DOX was sufficient to increase invasion of tumor organoids
after 4 and 7 days’ incubation. This was accompanied by an in-
crease in the number of tubular structures particularly at day 7
(Figures 7A and 7B). Tubular structures incubated with CM+DOX
display an increase in the area and number of branches. This was
not due to increased proliferation since round organoids do not
show these differences (Figures 7C and 7D). Branches are locally
regulated invasive epithelial buds essential for formation of the
mammary gland (Sternlicht, 2006); thus, the increase in tubular
organoids and branching further supports a role for CM+DOXFigure 6. Increased ROS Levels in Cells with Extra Centrosomes Drive
(A and B) (A) Levels of intracellular ROS using DCFDA or (B) by measuring the ra
(C) NRF2 protein levels in the cytosolic and nuclear fractions.
(D) Gene expression profile of cells with extra centrosomes (48 hr) compared to
(E) IL-8 secretion in after NAC treatment.
(F) Quantification of invasive structures.
(G) Left, cells stained for b-galactosidase (blue). Right, quantification of b-galact
(H) Left, quantification of gH2AX foci. Right, cells were stained for DNA (green) and
DOX+H2O2 = 518; +DOX = 466; +DOX+H2O2 = 377. Scale bar: 20 mM.
(I) Quantification of invasive structures.
(J) Ratio of GSH/GSSG.
(K) IL-8 secretion in cells treated with apocynin.
(L) Quantification of invasive structures. For all graphics error bars, represent mea
****p < 0.0001; ns not significant.
See also Figure S6 and Table S1.in promoting invasion. The formation of branches is controlled
via paracrine interactions and requires HER2 signaling (Stern-
licht, 2006), similar to paracrine-induced invasion by cells with
extra centrosomes.
We found that CM collected from breast cancer cell lines with
extra centrosomes (MDA-231 and BT-549) was also able to
increase paracrine invasion of MCF10A cells, suggesting that
this effect is not restricted to non-transformed cells. This further
emphasizes that non-cell-autonomous invasion induced by
centrosome amplification does not require cells to be senescent
(Figures 7E and S7O). Using the Cancer Cell Line Encyclopedia
(CCLE) database, we found a correlation between centrosome
amplification and the expression of the secreted pro-invasive fac-
tors, excluding GDF-15, in a panel of breast cancer cell lines (Fig-
ures 7E and 7F), which we previously characterized for centro-
some amplification (Rhys et al., 2018). Importantly, induction of
centrosome amplification in the breast cancer cells lines MCF-7
(p53 WT) and HCC-1954 (p53 mutant), which are of luminal and
basal origin, respectively, was also sufficient to induce paracrine
invasion in the recipient MCF10A cells (Figure 7G and Table S1).
Thus, centrosome amplification-induced paracrine invasion is
independent of the breast cancer subtype and can occur in the
presence of at least some p53 mutations. In the case of HCC-
1954 harboring the missense c.488A>G p53 mutation, increased
ROS was observed upon induction of extra centrosomes (Fig-
ure S7P). Therefore, the presence of extra centrosomes elicits
a similar non-cell-autonomous phenotype in non-transformed
and cancer cells. Taken together, we propose that a stress
response downstream of extra centrosomes leads to the secre-
tion of proteins, partly mediated by increased ROS, that promote
an invasive behavior in the surrounding cells (Figure 7H).
DISCUSSION
Our study establishes that the impact of extra centrosomes in
tumors goes beyond altering the biology of cells that carry this
abnormality by promoting non-cell-autonomous invasion. Struc-
tural centrosomal abnormalities have been recently shown to
play non-cell-autonomous roles by changing the biomechanical
properties of the epithelium leading to the budding of mitotic
cells (Ganier et al., 2018). Here, we show that non-cell-autono-
mous invasion promoted by centrosome amplification is medi-
ated by a secretory response that culminates with the secretion
of multiple pro-invasive factors, including IL-8, ANGPTL4, PAI,Secretion
tio of GSH/GSSG (48 hr).
an NRF2 (NFE2L2)-induced gene-set signature.
osidase positive cells. Scale bar: 40 mM.
gH2AX (magenta). L, large nuclei. Number of cells MCF10A.PLK4DOX = 469;
n ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001,
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Figure 7. Centrosome Amplification in Breast Cancer Mediates Paracrine Invasion and Is Associated with IL-8 Secretion
(A) Quantification of round invasive and tubular structures in PyMT-derived tumor organoids.
(B) Tumor organoids. Scale bar: 20 mM.
(legend continued on next page)
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MSN, and GDF-15, previously implicated in cancer invasion
(Chang et al., 2012; Duffy, 2004; Tan et al., 2012; Wang et al.,
2017; Waugh and Wilson, 2008). The combination of some of
these factors (IL-8, ANGPTL4, and GDF-15) was sufficient to
induce paracrine invasion, suggesting that multiple pathways
are involved. One of the pathways important for this process is
HER2 signaling, which can be activated by Src kinase down-
stream of the IL-8-CXCR1/2 axis (Singh et al., 2013). It is still
unclear which pathways downstream of GDF-15 and ANGPTL4
are involved. In cancer, the cognitive receptor for GDF-15 is un-
known; however, the C-terminal fragment of ANGPTL4, used in
this study, can bind and activate b1 and b5 integrins, which could
aid invasion (Goh et al., 2010). In breast cancer cells, centrosome
amplification drives paracrine invasion and is correlated with the
expression of pro-invasive factors, highlighting the importance
of these findings in cancer.
IL-8, a recognized pro-inflammatory chemokine, is overex-
pressed in tumors and plays roles in invasion, proliferation, and
survival of tumor cells, as well as in angiogenesis and immune
infiltration (Liu et al., 2016; Waugh and Wilson, 2008). Conse-
quently, elevated serum levels of IL-8 are associated with distant
metastasis and considered an unfavorable prognostic factor in
breast cancer (Benoy et al., 2004; Milovanovic et al., 2013).
How IL-8 expression and secretion is regulated in tumors is
not completely understood. IL-8 regulation occurs mostly at
the transcriptional level, and its expression is induced by inflam-
matory signals (e.g., tumor necrosis factor a, IL-1b), environ-
mental stresses (e.g., hypoxia) and exposure to chemotherapy
agents (e.g., 5-fluorouracil, paclitaxel) (Waugh and Wilson,
2008). We found that centrosome amplification can lead to
increased IL-8 expression. Moreover, our data suggest that early
IL-8 secretion is induced by NOX-mediated ROS production.
These findings are reminiscent of what has been observed in
neutrophils in which rapid release of IL-8 was shown to be a
consequence of NOX-induced ROS (Hidalgo et al., 2015). Our
work suggests that the presence of extra centrosomes could
regulate IL-8 production and/or secretion in tumors. Supporting
this idea, we found that IL-8 expression correlates with centro-
some amplification in breast cancer cell lines. Moreover, breast
cancer stem cells with high levels of the ubiquitin-specific prote-
ase 44 (USP44) display centrosome amplification and increased
IL-8 expression, which promotes vascularization and predicts
aggressive behavior (Liu et al., 2015).
Generation of ROS is vital to redox signaling. To prevent oxida-
tive stress, ROS levels are exquisitely balanced by pro- and
antioxidants (Terada, 2006). This balance is often perturbed in
cancer, leading to overall higher ROS levels. However, because
high levels of ROS are toxic, tumors develop strong antioxidant
mechanisms to prevent cell death (Harris et al., 2015). NRF2,
one of the major regulators of antioxidant responses, is often(C) Area and branching of the tumor organoids. Error bars represent mean ± SEM
(D) PyMT tubular organoids. Scale bar: 100 mM.
(E) Levels of centrosome amplification and breast cancer subtype.
(F) mRNA expression levels of pro-invasive factors.
(G) Quantification of invasive structures.
(H) Schematic representation of how centrosome amplification promotes secreti
Unless specified, for all graphics, error bars represent mean ± SD from three ind
See also Figure S7 and Table S1.stabilized in response to oncogenes such as K-RAS and MYC
and is essential for tumor detoxification and growth (DeNicola
et al., 2011; Sporn and Liby, 2012). We demonstrate that NFR2
is also stabilized and accumulates in the nucleus where it
drives an antioxidant transcriptional response downstream of
centrosome amplification. This could be important to prevent
ROS-induced damage and a vital adaptation mechanism to
centrosome amplification. ROS increase in cells with amplified
centrosomes appears to be mediated by p53 stabilization, since
p53 depletion decreases ROS-mediated IL-8 secretion and pre-
vents paracrine invasion. This is consistent with the central role
of p53 in ROS production (Liu et al., 2008). p53 overexpression
was shown to increase ROS levels via transactivation of several
ROS-generating enzymes such as NQO1 as well as p67phox, an
activating subunit of NOX2 complex, while suppressing the
expression of antioxidant genes (Drane et al., 2001; Italiano
et al., 2012; Polyak et al., 1997; Vousden and Lane, 2007).
At higher levels, ROS can mediate senescence and apoptosis
downstream of p53 (Vigneron and Vousden, 2010; Wiley and
Campisi, 2016). Indeed, centrosome amplification can induce
senescence in a fraction of RPE-1 and BF cells. However, in
MCF10A cells, centrosome amplification only induced a senes-
cence-like response. This is consistent with our findings demon-
strating that MCF10A cells do not develop a strong SASP.
This further supports that the early secretory response we
observe in these cells precedes senescence. The differences
in response to centrosome amplification fit with the idea that
the type and extent of the p53-inducing stress and/or cellular
context determines the outcome of ROS production (Kasten-
huber and Lowe, 2017). Thus, it is plausible that the response
to ROS downstream of extra centrosomes varies among cell
types, and it will be interesting to investigate if this would culmi-
nate with different secretory signatures. It also suggests that only
cells with robust antioxidant mechanisms are able to resist
centrosome amplification-induced senescence. Intriguingly,
both in tumors and liver, where strong antioxidant mechanisms
are important for cell survival, accumulation of cells with extra
centrosomes can be observed without induction of a senes-
cence phenotype (Duncan, 2013; Gorrini et al., 2013), (Schwabe
and Brenner, 2006). We propose that in order for these cells to
efficiently proliferate, they require effective mechanisms to
prevent ROS-induced senescence. Since cellular senescence
can act as a safeguard against tumorigenesis, it is possible
that escaping from ROS-induced senescence could allow cells
with extra centrosomes to become tumorigenic while affecting
the surrounding cells via paracrine signaling.
Recent work showed that supernumerary centrosomes are
sufficient to drive tumorigenesis in mice (Levine et al., 2017).
Although these tumors show recurrent aneuploidies, the role of
aneuploidy in the initiation of extra centrosome-derived tumors.
on and paracrine invasion.
ependent experiments. *p < 0.05, **p < 0.01; ns, not significant.
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remains elusive. Ourwork, demonstrating that centrosome ampli-
fication induces ROS production, suggests that ROS signaling
and DNA mutagenesis could play a role in tumor initiation. These
findings also highlight ROS as a potential weakness of cells with
extra centrosomes, and perhaps therapies that specifically target
antioxidant pathways, currently under clinical trials, could be crit-
ical in targeting these cells (Gorrini et al., 2013). Indeed, we found
that low doses of H2O2 decrease the proliferation of cells with
extra centrosomes. The demonstration that centrosome amplifi-
cation alters protein secretion indicates that cells carrying extra
centrosomes have the ability to change the surrounding tumor
cells as well as the tumor microenvironment. Hence, as the ther-
apeutic potential of targeting subset of cells with extra centro-
somes within a tumor remains uncertain (Godinho and Pellman,
2014), our findings raise the exciting possibility that targeting
these cells could have a bigger impact in the clinic than antici-
pated. The notion that cells with extra centrosomes could be a
source of pro-tumorigenic factors, such as IL-8, indicates that
tumors could benefit from having cells with extra centrosomes.
We postulate that these non-cell-autonomous advantageous
effects could help to explain why cells with amplified centro-
somes, despite their fitness cost, are kept during tumor evolution.STAR+METHODS
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Chemicals, Peptides, and Recombinant Proteins
Doxycycline hyclate Sigma-Aldrich #D9891
RO-3306 Sigma-Aldrich #SML0569
Trastuzumab Genentech N/A
Erlotinib Santa Cruz #sc-202154
PHA-66752 Sigma-Aldrich #PZ0147
NSC23766 Millipore #553502
Reparixin Cayman Chemical #21492








Apocynin Santa Cruz #sc-203321
Antimycin-A Abcam #ab141904
DMEM/F12 Sigma-Aldrich #D8437
DMEM Thermo Fisher Scientific #41966-029
RPMI Thermo Fisher Scientific #21875-034
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Cholera toxin Sigma-Aldrich #C8052
Penicillin/Streptomycin Thermo Fisher Scientific #15140-122
Horse serum Sigma-Aldrich #H1138
FBS #10500-064
Tet-free FBS Hyclone #SH30070.03T
Blasticidin Generon #2805-10
Geneticin (G418) Thermo Fisher Scientific #10131027
Polybrene Sigma-Aldrich #H9268
Immobilized trypsin, TPCK treated agarose resin Thermo Fisher Scientific #20230
CellTracker Green CMFDA Thermo Fisher Scientific #C2925
CellTracker CM-Dil Dye Red Thermo Fisher Scientific #C7001
Tricaine Sigma-Aldrich #E10521
Formaldehyde 16% Thermo Fisher Scientific #28908
Formalin Sigma-Aldrich #HT5012
Phalloidin Alexa A568 Molecular Probes #12380
Hoechst 33342 Molecular Probes #H3570
Mitosox Molecular Probes #M36008
ProLong anti-fade mounting medium Molecular Probes #P36934
BSA Sigma-Aldrich #A9647
Lipofectamine 2000 Invitrogen #11668027
Lipofectamine RNAi Max Invitrogen #13778075
Power SYBR Green PCR Master Mix Applied Biosystems #4367659
RIPA Buffer Thermo Scientific #89901
Complete Mini Protease Inhibitor Cocktail Roche #11836153001
Phosphatase inhibitor Cocktail Cell Signaling #5870
Bradford Protein Assay Bio-Rad #5000006
Insulin-Transferrin-Selenium-Ethanolamine (ITS) Thermo Fisher Scientific #51500-056
Liberase Research Grade Sigma-Aldrich 5401020001
Human IL-8 R&D #208-IL-010
Human C-terminal ANGPTL4 R&D #4487-AN-050
Human GDF-15 Invitrogen #EHGDF-15
Human FGF Sigma-Aldrich #F0291
Critical Commercial Assays
ELISA GDF-15 kit Thermo Fisher Scientific #EHGDF15
ELISA IL-8 kit Abcam #ab46032
ELISA PAI kit Abcam #ab108891
ELISA Mesothelin kit R&D #DMSLN0
ELISA Angiopoietin-like 4 kit Thermo Fisher Scientific #EHANGPTL4
ELISA HMGB1 kit IBL #ST51011
RNAeasy kit Qiagen #74104
High-capacity RNA-to-cDNA kit Thermo Fisher Scientific #4387406
Power SYBR Green Thermo Fisher Scientific #4367659
Pierce LDH Cytotoxicity Assay kit Thermo Fisher Scientific #88953
Senescent cells histochemical staining kit Sigma-Aldrich #CS0030-1KT
Cellular Reactive Oxygen Species detection kit Abcam #Ab113851
GSH/GSSH-Glo assay Promega #V6611
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BCA Protein assay Thermo Fisher Scientific #23225
Human phosphor-receptor tyrosine kinase array kit R&D #ARY001B
Proteome Profiler Human XL Oncology array kit R&D #ARY026
Custom Human antibody array kit RayBiotech #AAH-CUST-M
Deposited Data
Microarray Data ArrayExpress E-MTAB-6415
Experimental Models: Cell Lines
MCF10A ATCC #CRL-10317
MCF10A.PLK4 Godinho et al. (2014) N/A
HaCaT.PLK4 Godinho et al. (2014) N/A
BF.PLK4 This work N/A
RPE1.PLK4 Rhys et al. (2018) N/A
MCF-7.PLK4 This work N/A
HCC1954.PLK4 This work N/A
BT-549 Prof. Peter Schmid (QMUL) N/A
MDA-MB-231 Prof. Peter Schmid (QMUL) N/A
MDA-MB-468 Prof. Peter Schmid (QMUL) N/A
HEK293M Prof. David Pellman (DFCI) N/A
Experimental Models: Organisms/Strains
Mouse: Mus musculus C57BL/57 strain Charles River JAX C57BL/6J
Mouse: Mus musculus B6.129S2(C) – Cxcr2tm1Mwm/J Jackson Laboratory #006848
Zebrafish: Danio rerio mitfaw2/w2; mpv17a9/a9 (Casper) N/A N/A
Oligonucleotides
siRNAs – See Table S6 N/A
qRT-PCR primers – See Table S7 N/A
Recombinant DNA
pLenti-CMV-TetR-Blast Addgene #17492
pLenti-CMV/TO-Neo-DEST.PLK4 Godinho et al. (2014) N/A
pInducer.PLK4 Rhys et al. (2018) N/A
pMD2.G VSV-G Addgene #12259
psPAX2 Gag-Pol Addgene #12260
Other
Vivaspin columns MWCO 5000 Da GE Healthcare #28-9323-59
8-well chamber slides Corning #354108
8-well chamber slides with glass bottom ibidi #80827CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Susana A.
Godinho (s.godinho@qmul.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
Cell lines were maintained at 37Cwith 5%CO2 atmosphere. Humanmammary epithelial MCF10A cells were grown in DMEM/F12
supplemented with 5% donor horse serum, 20 ng/ml epidermal growth factor (EGF), 10 mg/ml insulin, 100 mg/ml hydrocortisone,
1 ng/ml cholera toxin, 100 U/ml penicillin and streptomycin. HaCat (human keratinocytes; gift from J. Marshall-QMUL), BF (primary
human fibroblasts; gift from A. O’Loghlen-QMUL), MDA-468 andMDA-231 (breast cancer; gift from P. Schmid-QMUL) were grown
in DMEM supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. RPE-1 (human retinal epithelial) were grown
in DMEM/F12 supplemented with 10% FBS and 100 U/ml penicillin and streptomycin. MCF-7, HCC1954 and BT-549 (breast can-
cer; gift from P. Schmid-QMUL) were grown in RPMI supplemented with 10% FBS and 100 U/ml penicillin and streptomycin.Developmental Cell 47, 409–424.e1–e9, November 19, 2018 e3
Tetracycline-free FBS was used to grow cells expressing the PLK4 Tet-inducible construct, with the exception of MCF10A cells
where horse serum was always used.
For 3D cultures, MCF10A cells were grown in the same medium with reduced horse serum (2%). To assay invasion in 3D cultures,
cells were grown in a mix of matrigel: collagen-I, as previously described (Arnandis and Godinho, 2015). Growth factor-reduced
matrigel with specific protein concentrations between 9 and 11 mg/ml was used. Note that due to the variability in the composition
of the matrigel lots, we always tested the ability of cells with extra centrosomes to induce the formation of invasive protrusions
(20%) before we use it for our experiments.
Collagen-I was used at 1.6 mg/ml. Cells were grown for 4 days in 3D cultures before quantifying invasion. 150–200 acini were
scored per condition for each experiment.
Mouse Mammary Organoids
Mammary gland organoids were prepared according to previously describedmethods (Nguyen-Ngoc et al., 2015). Briefly, mammary
glands fromC57BL/6J female mice between 8 and 12 weeks of age were isolated. In the sterile hood, mammary glands were minced
with a scalpel, and the small pieces were transfer to a collagenase solution in DMEM/F12 (2 mg/mL collagenase, 2 mg/mL trypsin,
5 % v/v fetal bovine serum (FBS), 5 mg/mL insulin and 50 mg/mL gentamicin) on a shaker (150 rpm) for 35 min at 37C. Tubes were
spun in a centrifuge at 1500 rpm for 10 min at room temperature and the pellet was kept as the epithelial fraction containing the
organoids. After further digestion of the pellet with DNase (2 U/mL), three more short-pulse washes at 1500 rpm were done, and
organoid density was calculated by manual counting on the microscope. The structures were seeded at a 2 organoids/ml density
and embedded in a mixture of Matrigel: Collagen (3:7) on eight well chambers. Organoid medium (DMEM/F12 with 1% penicillin/
streptomycin, 1% ITS and 2.5 nM FGF2) was added on top and invasive organoids were quantified after 4 days. Mammary organoids
were fixed with formaldehyde 4% and stained with a-SMA, Phalloidin and Hoechst 33342. Images were taken with a 710 Zeiss laser
scanning confocal microscope. We quantified 100 organoids per conditions for each experiment.
C57BL/6J WT animals were obtained from Charles River: https://www.criver.com/products-services/find-model/jax-c57bl6j-
mice?region=3616. CXCR2-/- BALB/c mice (Cxcr2tm1Mwm knock-out) were obtained from Jackson Laboratories (Cacalano et al.,
1994). WT littermates were used as controls. All animal experiments followed Home Office Guidelines determined by the Animals
(Scientific Procedures) Act 1986.
Zebrafish Embryo Xenograft Model
Zebrafish (Danio rerio) were handled in compliance with local animal care regulations (Queen Mary University of London) under the
Animals (Scientific Procedures) Act 1986 and standard protocols. Fish were kept at 28C in aquaria with day/night light cycles (10 hr
dark/14 hr light periods). The developing embryos were kept in an incubator at constant temperature.
MCF10A cells (1x106 cells) with normal or extra centrosomes (+DOX, 48 hrs) were stained in suspension with 10 mmol/L
CellTracker Green CMFDA (Green) or 2.5 mg/ml CellTracker CM-DiI Dye (Red) during 30 min at 37C. To remove unincorporated
dye, cells were rinsed twice with PBS, and one third of the cells of each condition was mixed 1:1 for the co-injection experiments
(300-400 cells per embryo). 48 hr old zebrafish embryos were dechorionated and anesthetized with tricaine (Sigma-Aldrich) prior
to implantation of the labelled cells in the perivitelline cavity with amanual injector (Picospritzer III, Parker Hannifin Instruments). After
injections, embryos were incubated at 34C. Three separate experiments were carried out per condition. Counting of disseminated
cells was done 24 hrs after injections under high magnification using a Zeiss Axioplan epifluorescence microscope.
Mouse Tumor Organoids
MMTV-PyMT cell isolation and growth has been previously described (Ogura et al., 2017). Briefly,MMTV-PyMT tumorswere isolated,
mechanically minced and chemically digested using Liberase and DNase I in HBSS and passed through a 100 mm cell strainer.
A single cell suspension of this PyMT primary tumor cells were seeded on a glass-bottom 8-well chamber at 2.5 x 103 cells/chamber
in a 2:1 mixture of Collagen-I (Corning) and Matrigel (Corning) yielding a final collagen concentration of 4 mg/ml and a final Matrigel
concentration of 2 mg/ml. Tumor organoids were grown in conditioned media supplemented with 10X concentrated MEM media
(DMEM/F12 supplemented with 2% FCS, 10 mg/ml Insulin, 20 ng/ml EGF and 1:50 L-Glutamax at 37C and 5% CO2 during
7 days. Tumor organoids were fixed with formaldehyde 4% and stained with Phalloidin and Hoechst 33342. Images were taken
with a 710 Zeiss laser scanning confocal microscope. The degree of branching and percentage of tubular and rounded structures
was manually quantified. Organoid growth and tubular expansion was obtained as the total Phalloidin area/structure using Image
J Software. We quantified 100 organoids per condition for each experiment.
METHOD DETAILS
Lentiviral Production and Infection
Cells expressing the inducible PLK4 construct were previously described (Godinho et al., 2014). Briefly, the lentiviral vectors pLenti-
CMV-TetR-Blast and p-Lenti-CMV/TO-Neo-Dest expressing the PLK4 cDNA were used consecutively. Cell lines were initially in-
fected with a lentivirus containing the TetR and selected using Blasticidin (5-10 mg/ml). After selection cells were secondarily infected
with the PLK4 containing lentivirus and selected with Geneticin (100-200 mg/ml). The selected cells were maintained as a pool toe4 Developmental Cell 47, 409–424.e1–e9, November 19, 2018
make a cell population. To generate the HCC1954.PLK4 and BF.PLK4 cell lines we used the pInducer21 lentiviral vector in which the
PLK4 cDNA was inserted using the Gateway system. In this case, positive cells were sorted according to GFP signal.
To generate lentivirus, HEK-293M cells were grown in antibiotic free medium and co-transfected with the lentiviral plasmid, VSV-G
(pMD2.G) and Gag-Pol (psPAX2) using Lipofectamine 2000, according to the manufacturer’s protocol. Lentivirus were harvested 24
and 48 hrs post infection and passed through a 0.45 mM syringe filter unit and stored at -80C. To infect cells, 8 mg/ml polybrene was
included to 1.5 ml of lentivirus and added on top of cells for 6 hrs. This process was repeated the following day and 48 hrs post initial
infection. As specified above cells were treated with appropriate antibiotic for selection or amplified for cell sorting.
Conditioned Media
Cells were seeded in a 6 well plate (-DOX: 0.7x105 cells/well; +DOX: 0.9x105 cells/well) and incubated for 2 days in the presence
or absence of DOX (2 mg/ml) until they reached 80%-85% confluency. After incubation, cells were washed three times with PBS
to remove DOX and 900 ml phenol-free DMEM/F12 medium without serum was added on top of the cells during 16 hrs. After that,
the conditioned medium (CM) was collected, centrifuged at 2,000g for 10min and filtered through a 0.2 mmpore filter. CMwasmixed
with 10X concentrated 3Dmedia (final concentration 1x) before being added on top of the 3D cultures. Cells were always counted to
discard effects due to differences on cell number. If a particular treatment decreased the final cell number, cell seeding was adjusted
so that the same cell numbers were obtained at the time of CM collection.
Trypsin treatment of the CM was done by adding 50 ml of beads with immobilized trypsin (TPCK Treated Agarose Resin) to 1 ml of
conditioned media and incubated overnight with rotation at 37C. The following day beads were removed by centrifugation and the
CM was added on top of 3D cultures.
Vivaspin columns with a 5kDa cut-off membrane were used to separate larger fractions (>5kDa: proteins) from smaller fractions
(<5kDA: metabolites, small molecules). 2 ml of conditioned media were added to the columns and centrifuged at 5000g for
30min. When drugs were present in the CM, Vivaspin columns were washed away with phenol-free DMEM/F12medium using 2 suc-
cessive centrifugations before resuspending the remainder CM with DMEM/F12.
Chemicals
Doxycycline (DOX) was used at 2 mg/ml. The following doses of inhibitors were used: 5 mMR0-3306 (CDK1i), 40 mg/ml Trastuzumab
(Herceptin, HER2 inhibitor), 0.5-4 mMErlotinib (EGFR inhibitor), 1 mMPHA-66752 (c-met inhibitor), 25 mMNSC23766 (RAC1 inhibitor),
100 nM Reparixin (CXCR1/2 inhibitor), 100 nM SCH563705 (CXCR1/2 inhibitor), 20 mM PD98059 (ERK inhibitor), 5 mM PP2 (Src
inhibitor), 100 mM H2O2 (Sigma), 5 mM NAC (Sigma), 0.5 mM Apocynin, 35 mM Antimycin-A, 10 mM Mitotempo, 5 mM Nutlin-3
and 100 ng/ml Doxorubicin (DoxoR).
Recombinant Proteins
Recombinant proteins were used at the following concentrations: IL-8 (0.5 mg/ml, 208-IL-010), c-terminal fragment of Angiopoietin-
like 4 (4 mg/ml) and GDF-15 (0.01 mg/ml).
Indirect Immunofluorescence 2D
Cells plated in glass coverslips (2D) were washed in PBS and fixed with ice-cold methanol at -20⁰C for 10 min for centrin2 staining.
Following fixation cells were permeabilized in 0.2% Triton X-100 in PBS for 5min and blocked in blocking buffer (PBS, 5%BSA, 0.1%
Triton X-100) during 30min. Cells were then stained in primary antibodies diluted in blocking buffer for 60min. Cells were washedwith
PBS and incubated 60 min with species-specific fluorescent secondary antibodies (Alexa-conjugated). DNA was stained with
Hoechst 33342 (1:5000) for 5 min in PBS. Antibodies used included: anti-a-tubulin DM1a (1:1000), anti-centrin-2 N-17-R (1:100).
For all conditions used in this work, centrosome amplification was determined as the percentage of mitotic cells containing extra
centrosomes (Table S1). For Ki67 staining (assess cell viability) or gH2AX (assess dsDNA breaks), cells were fixed with 4% of form-
aldehyde 15 min at room temperature and stained using anti-Ki 67 antibody (1:500) and anti-gH2AX (1:200) diluted in 0.25% BSA.
Images were acquired using an inverted Nikon microscope coupled with a spinning disk confocal head (Andor) and analyzed with
ImageJ (National Institute of Health, Bethesda, MD, USA). Proliferating cells were quantified as the percentage of Ki67 positive nuclei
and dsDNA breaks were quantified as the number of gH2AX-positive foci per nucleus using the NIS-Elements software (Nikon).
To assess mitochondrial ROS, live cells were incubated with 5 mMMitosox for 10 min at 37⁰C. Images were acquired using an in-
verted Nikon microscope coupled with a spinning disk confocal head (Andor). Images were analyzed with NIS-Elements software
(Nikon). 100 cells in mitosis were used to quantify centrosome amplification per condition for each experiment.
Indirect Immunofluorescence 3D
Immunostainings of 3D cultures were performed on partially embedded 3D acini and breast and tumor organoids, both plated on
eight-well chambers, according to previous protocols (Godinho et al., 2014; Ogura et al., 2017). Briefly, the media was removed
and the structures were washed with PBS and fixed in 5% of formalin in PBS for 20 min at 37C. After fixation cells were washed
3 times, 10 min each, with PBS: 100 mM glycine and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were blocked
with 10% goat serum in IF buffer (130mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton
X-100, 0.05% Tween-20) for 1 hr at room temperature, and primary antibodies were incubated in this solution over night at 4C. Cells
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temperature (Alexa-conjugated). Cells were washed twice with IF buffer and once with PBS followed by 10 min incubation with
Hoechst 33342 (1:2500). 3D cultures were mounted in ProLong Antifade mounting medium. Antibodies used include anti Laminin-V
AlexaFluor 488 conjugated (1:100) and a-smoothmuscle actin (1:150). For f-actin staining 3D cultures were incubated with Phalloidin
(1:100; AlexaFluor 568) for 60 min. Images were taken with a 710 Zeiss laser scanning confocal microscope.
Long-Term Live-Cell Imaging
MCF10A cells plated in ibidi chambered slides were used for 3-D imaging. Cells were imaged on a Nikon Eclipse Ti-E inverted
microscope equipped with a ORCA-Flash 4.0 camera, a precision motorized stage, and Nikon Perfect Focus, all controlled by
NIS-Elements Software (Nikon). Microscope was enclosed within temperature and CO2-controlled environments that maintained
an atmosphere of 37 C and 3%-5% humidified CO2. Phase contrast images were captured at every 10 minutes for 20 hrs with
either Plan Fluor 10X (0.3 NA) or Plan Apo VC 20X (0.75 NA) objectives. Captured images from each experiment were analyzed using
NIS-Elements software. Videos were played at 50 ms per frame.
ELISAS
Levels of secreted proteins were assessed in the CM collected from cells with normal or extra centrosome numbers (+DOX) using
commercially available ELISA kits, following manufacturer’s instructions: GDF-15, IL-8, PAI, Mesothelin, Angiopoietin-like 4 and
HMGB1. Briefly, CM, collected as described above (see CM section), and specific protein standards were loaded on the specific-
antibody coated wells of the supplied microplate, which bind to the immobilized (capture) antibody. A sandwich is formed by the
addition of the biotinylated antibody, binding to the chemokine on a different epitope from the capture antibody. A conjugated
enzyme (Streptavidin-Peroxidase) was added into the assay. After incubation periods and wash steps specified by every supplier
to remove unbound antibody from the plate, a substrate solution was added in order to obtain a measurable signal. The intensity
of this signal was proportional to the concentration of the protein present in the CM. Assays were performed in triplicate, and absor-
bance at 450 nm was read on a plate reader.
Nuclear Fraction Isolation
70% confluent cells on a 6-well plate were washed twice and scraped with PBS. This fraction was centrifuged at 850 g for 10 min to
collect the cells. Cells were then lysed by 15 min incubation in hypotonic buffer (20 mM HEPES [pH 7.6], 20% glycerol, 10 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 25 mM NaF, 25 mM b-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride,
1 mM sodium orthovanadate, 1 mM dithiothreitol, and protease inhibitors) supplemented with detergents (NP-40, 10%). After this
incubation, nuclei were collected by centrifugation (14000 g for 1 min at 4◦C) and supernatant recovered as cytosolic fraction.
This pellet, including mainly intact nuclei, was lysed in a rocking platform for 30min with gentle agitation and nuclear soluble fractions
were collected after centrifugation (14000 g for 10 min at 4◦C).
Western Blotting
Cells were collected and resuspended in RIPA buffer supplemented with protease and phosphatase inhibitors. Protein concentration
was quantified using the Bradford Protein Assay (20 mg was loaded per well). Protein samples were then resuspended in
Laemmli buffer and separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto
PVDF membranes. Antibodies used included anti-p53 (1:1000), anti-p21 (1:1000), anti-b-actin (1:5000), anti-a-tubulin (1:2000),
anti-Histone H3 (1:10000), anti-Interleukin-8 (1:1000), anti-NRF2 (1:1000), anti-ERK (1:1000), anti-pERK Thr202/Tyr204 (1:1000),
pEGFR Tyr1068 (1:1000) anti-MCAK (1:1000), anti-N-cadherin (1:500), anti-E-Cadherin (1:500), anti-Vimentin RV202 (1:500), anti-
pHER2 Tyr1221/1222 (1:1000) and anti-p-c-Met Tyr1234/1235 (1:1000). Western blots were developed using SRX-101A Konica
Minolta and scanned. The intensity of the bandswasmeasured by densitometry using ImageJ (National Institute of Health, Bethesda,
MD, USA).
To assess the levels of p-Erk1/2, cells pre-treated with HER2 (Trastuzumab, 40 mg/ml, 1 hr) and CXCR1/2 (SCH563705, 100 nM,
1 hr) inhibitors and incubated with CM for 10 min.
siRNA
siRNA was performed using Lipofectamine RNAiMax. 50 nM of siRNA was used per well in a 6-well plate. Cells were incubated with
the transfection mix for 6 hrs, washed and normal growth medium was added. Cells were analyzed 48 hrs post transfection. siRNAs
used are described in Table S5. To assess invasion in the siRNA mini screen, 150-200 acini were quantified per conditions in each
experiment.
qRT-PCR
RNA was prepared using the Qiagen RNAeasy kit according to the manufacturer’s instructions. 200 ng of RNA was used to produce
cDNA using the High-Capacity RNA-to-cDNA kit according to the manufacturer’s instructions. For qRT-PCR we used Power SYBR
Green followed by analysis with 7500 Real Time PCR system (Applied Biosystems). All primers used for qRT-PCR are described in
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Secretomics Optimization
Secretome analysis was done in the CM collected from cells with normal or extra centrosomes (+DOX, 48 hrs). Since secreted pro-
teins are often masked by high amounts of protein supplements in the culture medium, we used a modified serum-deprived method
previously described (Acosta et al., 2013). After three washes with PBS, DMEM/F12phenol-free medium without serum was added
on top of the cells during 16 hrs. After this incubation, CMwas collected and cells were counted. The collected CMwas assessed for
protein concentration, measured using Bradford Protein Assay. Lactate dehydrogenase (LDH) detection was also assessed using a
the LDH Cytotoxicity Assay Kit, as a measure of cell death. Samples were concentrated using Vivaspin Columns (Vivaspin MWCO
5000 Da) before proceeding to the protein analysis by mass spectrometry.
Mass Spectrometry
Proteomics experiments were performed using mass spectrometry as reported before (Casado et al., 2013; Rajeeve et al., 2014).
Briefly, enriched CMproteins were digestedwith trypsin and resultant peptides were desalted using C18 plus carbon top tips (Glygen
corparation, TT2MC18.96) and eluted with 70% acetonitrile (ACN) with 0.1% formic acid. Dried peptides were dissolved in 0.1% TFA
and analyzed by nanoflow LC-MS/MS in an ultimate 3000 RSL nano instrument coupled on-line to a Q Exactive plus mass spectrom-
eter (Thermo Fisher Scientific). A PepMap RP 75 mm ID x 150mm columnwas used for peptide separation. Gradient elution was from
3% to 35% buffer B in 120 min at a flow rate 250nL/min with buffer A being used to balance the mobile phase (buffer A was 0.1%
formic acid in water and B was 0.1% formic acid in ACN). The mass spectrometer was controlled by Xcalibur software (version 4.0)
and operated in the positive ionmode. The spray voltagewas 1.95 kV and the capillary temperature was set to 255C. TheQ-Exactive
plus was operated in data dependent mode with one survey MS scan followed by 15 MS/MS scans. The full scans were acquired in
themass analyzer at 375- 1500m/z with the resolution of 70 000, and theMS/MS scans were obtained with a resolution of 17 500.MS
raw files were converted into Mascot Generic Format using Mascot Distiller (version 2.5.1) and searched against the SwissProt data-
base (release December 2015) restricted to human entries using the Mascot search daemon (version 2.5.0) (Perkins et al., 1999).
Allowed mass windows were 10 ppm and 25 mmu for parent and fragment mass to charge values, respectively. Variable modifica-
tions included in searches were oxidation of methionine and pyro-glu (N-term). Label-free quantification was performed by calcu-
lating the peak areas of extracted ion chromatograms (XICs) for the respective peptide ion. Mass and time windows were 7ppm
and 1.5minutes respectively. Pescal was used to automate the generation of XICs as described (Wilkes et al., 2015). To reliably differ-
entiate the extracellular components from intracellular contaminants, a filtering step was applied using different Databases: Gene
ontology, Secreted Protein Database and Signal Peptide Database. From the Secreted Protein Database ranks 0 to 2 were consid-
ered as belonging to the extracellular compartment.
Analyses of the Extracellular Protein Compartment
To define the proteins from the mass spectrometry data that belonged to the extracellular compartment we used several databases,
including Gene ontology, Secreted Protein Database and Signal Peptide Database. Secreted protein Database (SPD) consists of a
core dataset and a reference dataset (Chen et al., 2005). The core dataset contains 18 152 secreted proteins retrieved from Swiss-
Prot/TrEMBL, Ensembl, RefSeq and CBI-Gene. We used a combined automatic and manual processing to collect as much secreted
proteins as possible. The dataset Rank0 from Swiss-Prot includes some partial sequences without the N- or C-termini. Given that
most of the signal peptides are located at the N-terminal of proteins, we eliminated the entries without N-terminal methionine
(Met, M) in CBI-Gene, Ensembl, Swiss-Prot/TrEMBL and RefSeq in our prediction results. Proteins in the datasets of Rank1,
2, 3 all have N-terminal Met. For our analyses we selected proteins that ranked 0-2 as belonging to the extracellular compartment
since proteins in rank 3 have lower probability of belonging to the extracellular compartment (Chen et al., 2005).
b-Galactosidase Staining
Positive senescent cells were scored using a commercial available kit (Senescence Cells Histochemical Staining Kit). Briefly, cells
in 6-well plates were washed, fixed and stained overnight with a staining mixture at 37C without CO2. Under these conditions,
b-galactosidase activity is easily detectable in senescent cells, but undetectable in quiescent, immortal, or tumor cells. Percentage
of positive cells was counted manually with a microscope. We quantified 1500-2000 cells per conditions for each experiment. For
the H2O2 treatments, cells were incubated only 48 hrs with H2O2 after which cells were washed and left from the appropriate
time (6-10 days) before assessing senescence. As control positive, cells were treated with 100 ng/ml DoxoR for the entire duration
of the experiment.
Measure of ROS Production
ROS was measured using DCFDA (Cellular Reactive Oxygen Species Detection Assay Kit), a cell permeable fluorogenic dye that
measures hydroxyl, peroxyl and other reactive oxygen species (ROS) activity within the cell. Briefly, cells were plated after 48 hrs
of DOX treatment at a low confluency overnight (20x104 cells/ well) in 96 well transparent bottom black-plate. The following day,
the media was removed and 20 mM of DCFDA was added to the corresponding wells and incubated for 30 min at 37C. The dye
was washed away before reading. Positive controls were treated with 25 mM DoxoR for 3 hrs. The signal was detected by fluores-
cence spectroscopy with maximum excitation and emission spectra of 495 nm and 529 nm respectively.
ROS production was also assessed through the detection of oxidized proteins. Here we measure the total amount of oxidized
(GSSG) and reduced (GSH) glutathione using bioluminescent signals, according to manufacturer’s instructions (GSH/GSSG-GloDevelopmental Cell 47, 409–424.e1–e9, November 19, 2018 e7
Assay). Briefly, cells were plated at a low confluency overnight (12x104 cells/ well) in 96 well transparent bottom white-plate. The
following day, the media was removed and reduced glutathione lysis reagent or oxidized glutathione lysis reagent were added
to the corresponding wells and shake for 5 min at RT. Luciferin generation and detection reagent were added subsequently for
30 and 15 min, respectively. The bioluminescent signal was read per well using a plate reader luminometer. Final ratios were normal-
ized to protein concentration, which was determined per well using BCA Protein Assay Kit. NAC (5 mM) and Apocynin (0.5 mM) were
added at time of centrosome amplification induction (48 hrs) and DoxoR treatment was performed for 3 hrs (25 mM).
Human Phospho-Receptor Tyrosine Kinase Array
RTK activation was assessed using an antibody-based array (Human Phospho-Receptor Tyrosine Kinase Array Kit) following man-
ufacturer’s instructions. Briefly, cells were treated for 48hrs with CM collected from control cells and cells with extra centrosomes
(+DOX, 48hrs) and supplemented with completed medium. After incubation, cells were lysed using a lysis buffer provided by the
kit and protein concentration was determined using Bradford (Bio-Rad). 300 mg of protein cell lysates were added on top of the
membranes and incubated overnight at 2-8C on a rocking platform. Thereafter, a pan anti-phosphotyrosine antibody was added
to detect the activated RTKs. After several washes of the membranes, phosphorylated RTKs were spotted using a Chemi Reagent
Mix and developed in an autoradiography film cassette. Following quantification of scanned images using ImageJ software (National
Institute of Health, Bethesda,MD, USA) by densitometry, the relative activation of specific phosphorylated RTKs between normal and
cells with extra centrosomes was plotted.
Human XL Oncology Array Kit
We screened protein secretion using amembrane-based sandwich immunoassay (Proteome Profiler Human XL Oncology Array Kit),
following manufacturer’s protocol. Briefly, cell culture supernatants collected from normal or cells with extra centrosomes plated in
6-well plates were diluted and incubated overnight with themembrane arrays. Thesemembranes contain a set of capture antibodies,
spotted in duplicate, that bind to specific target proteins. The membranes were then washed to remove unbound material and incu-
bated with a cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent detection reagents were then
applied, and the signal was captured using autoradiography films. The intensity of every spot was measured by densitometry using
ImageJ (National Institute of Health, Bethesda, MD, USA) and the relative intensity versus control was calculated and depicted.
Human SASP Array Kit
MCF10A.PLK4 and RPE-1.PLK4 cells were seeded in a 6 well plate [MCF10A.PLK4: 0.7x105 cells for -DOX; 0.9x105 for +DOX and
2x105 for DoxoR (100ng/mL) and RPE-1.PLK4: 0.5x105 cells for -DOX; 0.75x105 for +DOX and 1.1x105 for DoxoR (100ng/mL)]
and incubated for 2 days in the presence or absence of DOX. For 48 hrs analyses, CM was collected as described above after
DOX treatment. For 7 days analyses, cells were split at day 2 and day 4 and serum free medium was added at day 6 and collected
at day 7. Senescence-Associated Secretory Phenotype (SASP) was screened using a membrane-based sandwich immunoassay
(Custom C-series Human Antibody Array), following manufacturer’s protocol. We defined a set of known SASP components,
including: including IL-8, IL-6, uPar, MIP-3a, MCP-1, GRO -a, -b, -c and IL-1b, based on previous work (Coppe et al., 2008), that
were spotted in duplicate on a membrane provided by RayBiotech. Cell culture supernatants collected from cells with normal or
extra centrosomes and cells treated with DoxoR were diluted in serum-free media and blocking solution. Volume equivalent to
2.105 cells/condition was incubated overnight with the membrane arrays. The membranes were then washed to remove unbound
material and incubated with a cocktail of biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent detection
reagents were then applied, and the signal was captured using autoradiography films. The intensity of every spot was measured
by densitometry using ImageJ (National Institute of Health, Bethesda, MD, USA) and the relative intensity versus control was calcu-
lated and depicted.
Microarray Analysis and GSEA
Total RNAwas extracted fromMCF10A.PLK4 untreated (-DOX) or treated with DOX (+DOX) for 48 hrs using the RNeasy kit. RNAwas
hybridized against the Affymetrix HG-U133_Plus_2 microarrays according to manufacturer’s instructions. Three biological replicates
(3 -DOX and 3 +DOX) were analyzed with two technical replicates each. Genes differentially regulated between –DOX and +DOX
groups were identified using limma with a false discovery rate (FDR) <0.05. Gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) was performed to investigate whether gene expression profiles of MCF10A cells with extra centrosomes (+DOX,
48 hrs) show bias towards specific signatures (http://software.broadinstitute.org/gsea/msigdb). In the GSEA, genes were ranked
by Z score corresponding to false discovery rate (FDR) adjusted p values of the expression differences between normal cells and
cells with extra centrosomes. 100,000 permutations were performed to assess the statistical significance of the enrichment score.
The Gene Set for NRF2-regulated genes can be found here: http://software.broadinstitute.org/gsea/msigdb/cards/NFE2L2.V2.html.
CCLE Expression Analysis
Raw mRNA abundance values for cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012).
Expression values for a subset of 14 cell lines were quantile normalized using Robust Multi-array Average (RMA). Each
cell line was assigned to a comparative group based on its centrosome amplification; high (BT-549, CAL-120, HCC-1937,
Hs578T, MDA-231), intermediate (HCC-1954, HCC-38, BT-474, HCC-1143, SK-BR-3, JIMT-1), and low (BT-20, MDA-468,e8 Developmental Cell 47, 409–424.e1–e9, November 19, 2018
MCF-7) (Figure 7C). Boxplots of the mRNA abundance levels of cell lines appertaining to each group were generated for a group of
pro-invasive factors.
Exosomes and Microvesicle Isolation
Isolation of microvesicles and exosomes was done by differential ultracentrifugation as described previously (Costa-Silva et al.,
2015). Briefly, CM was collected as described above and cell debris was pelleted by centrifugation at 500g for 10 min. Microvesicles
fraction was collected by centrifugation at 12,000g for 20 min. The supernatant was then centrifuge at 100,000g for 70 min in order
to obtain the exosomes. The exosome pellet was washed in 20 ml of phosphate-buffered saline (PBS) and collected by ultracentri-
fugation at 100,000g for 70 min (Beckman Ti70). Both microvesicles and exosomes were resuspended in 3D media up to the initial
volume in order to test their role in invasion.
DATA AND SOFTWARE AVAILABILITY
Microarray data of control MCF10A.PLK4 cells andMCF10A.PLK4 cells treated with DOX (48 hrs) to induce centrosome amplification
is publicly available at ArrayExpress, accession number E-MTAB-6415.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Appropriate statistical tests were applied as per described in each legend using GraphPad Prism 5.0. Briefly, student’s t-tests were
used for comparisons between two groups. One-way ANOVA with Tukey post hoc test were used for comparison of three or more
groups with one independent variable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant.Developmental Cell 47, 409–424.e1–e9, November 19, 2018 e9
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Figure S1. Centrosome amplification induces paracrine invasion. Related to Figure 1, Table S1, Videos S3 and S4. (A) 
Left, Cells in mitosis with normal and amplified centrosomes (>2 centro.; clustered + multipolar) were stained for 
microtubules (MTs) (a-Tubulin, red), centrioles (centrin2, green) and DNA (blue). Scale bar 10µm.  Right, Centrosome 
amplification in cells with extra centrosomes (+DOX) or incubated with CM collected from cells with extra centrosomes 
(CM+DOX). (B) Normal and invasive 3D acini stained for f-actin (phalloidin, red), laminin V (green) and DNA (blue). White 
arrowheads indicate invasive protrusions.  Scale bar 20µm. (C) Still images from live cell imaging of acini incubated with 
CM (CM-/+DOX). Red arrowheads indicate invasive acini and orange arrowhead indicates a cell/nuclei moving through the 
invasive protrusion. Scale bar 20µm (D) Left, Quantification of acini with invasive protrusions containing nuclei in cells 
with extra centrosomes (+DOX) or incubated with CM (CM-/+DOX). Right, Invasive acini stained for f-actin (phalloidin, red) 
and DNA (blue). Arrowheads indicate invasive protrusions.  Scale bar 20µm.  (E) Left, Quantification of invasive structures 
in acini with extra centrosomes (+DOX) and incubated with CM+DOX. Right, Highly invasive/disrupted acini observed in 
cells with extra centrosomes treated with CM+DOX. Cells were stained for f-actin (phalloidin, red) and DNA (blue).  Scale 
bar 20µm. (F) Quantification of invasive acini incubated with CM from HaCaT.PLK4 cells. (G) Schematic representation of 
SAS-6 depletion to revert centrosome amplification. (H) Quantification of invasive acini incubated with CM from cells 
where centrosome amplification was lost (SAS-6 siRNA).  (I) Invasive acini in cells incubated with CM collected from cells 
treated with the CDK1 inhibitor RO-3306 (5µM, 40 hrs). (J) Bright field images of non-invasive and invasive mouse 
mammary organoids.  Scale bar 50µm. For all graphics error bars represent mean +/- SD from three independent 









 Figure S2. Proteins secreted by cells with extra centrosomes promote paracrine invasion via RTK activation. Related 
to Figure 2. (A) Levels of E-cadherin, N-cadherin and Vimentin in cells incubated with CM for 4 days. TGF-b treatment (5 
ng/ml, 4 days) was used as positive control.  (B) Schematic representation of Vivaspin filtration and tryspin incubation. 
(C) Quantification of invasive acini cells incubated with CM after Vivaspin filtration. P: proteins, M: metabolites.  (D) 
phospho-RTK array obtained from cells incubated with CM.  (E) phospho-Her2 levels in cells treated with 40 µg/ml of 
Trastuzumab (Her2 inhibitor) for 1 hr. S, serum starved; +M, plus fresh medium. (F) phospho-c-Met levels in cells 
treated with 1 µM PHA-66752 (c-Met inhibitor) for 1 hr. S, serum starved; +M, plus fresh medium. (G) phospho-EGFR 
levels in cells treated with different concentrations of Erlotinib (1 and 4 µM, 24 hrs). (H) Left, Quantification of invasive 
acini cells treated with EGFR inhibitor (Erlotinib, 1 and 4 µM) and incubated with CM. Right, Acinar structures. Red 
arrowheads indicate invasive acini. Scale bar 40µm. (I) Table summarising the conditions used to prepare CM for 
proteomic analysis. Cells with (+DOX) or without extra centrosomes (-DOX) were plated at different densities to ensure 
a similar cell number by the time of CM collection. Protein concentration and invasive capacity of the CM was assessed 
in all samples. (J) Left, Schematic representation of the ultracentrifugation method to isolate MVs and Exo. Right, 
Quantification of invasive acini in cells incubated with CM with and without MVs/Exo.  (K) Human XL Oncology Array 
incubated with CM collected from cells with (CM+DOX) and without (CM-DOX) extra centrosomes. For all graphics error 





Figure S3. siRNA screen identified secreted pro-invasive factors in MCF10A cells with extra centrosomes. Related to 
Figure 3 and Table S1. (A) Schematic representation of the siRNA screen set-up.  (B) Acini images from 96-well plate 
siRNA screen. Scale bar 40µm. (C) mRNA levels for all the siRNA conditions to assess depletion efficiency. Red dashed 
line represents 50% reduction of mRNA levels. (D) Cell number upon siRNA treatment to assess the impact of the 
different conditions on cell proliferation/viability. Green asterisks depict the positive screen hits shown in Figure 3F. (E) 
Cell number in cells with extra centrosomes (+DOX) upon siRNA depletion of some of our positive hits. For all graphics 
















 Figure S4. Validation of the positive hits identified in the siRNA screen. Related to Figure 4. (A) Levels of secreted 
ANGPTL4. (B) Levels of secreted IL-8. (C) Levels of secreted MSN. (D) Levels of secreted GDF-15. (E) Levels of secreted 
PAI. (F) mRNA levels of the different pro-invasive factors after induction of centrosome amplification (48 hrs).  (G) 
Quantification of invasive structures in acini incubated with CM collected from cells depleted of IL-8 (siRNA pool and 
individual sequences). (H) Quantification of invasive structures in acini incubated with CM collected from cells depleted 
of IL-8 and supplemented with recombinant IL-8 (0.5 µg/ml). (I) IL-8 levels after siRNA depletion. (J) Non-invasive and 
invasive mammary organoids from WT mice stained for f-actin (phalloidin, red), a-SMA (green) and DNA (blue). Scale 
bar 20µm. (K) Left, Schematic representation of the zebrafish co-injections. Right, Quantification of the incidence of 
invasion in the co-injection experiments (-DOX/+DOX) when CXCR2 is depleted in cells with normal centrosomes (-DOX). 
Number of injected fish co-injection control siRNA=71; co-injection CXCR2 siRNA=121. For all graphics error bars 








Figure S5. Secretion of pro-invasive factors in cells with extra centrosomes does not require a full senescence 
response and is not a consequence of aneuploidy. Related to Figure 5 and Table S1. (A) Left, Quantification of b-
galactosidase positive MCF10A.PLK4 cells after induction of centrosome amplification for 10 days. Right, Images 
representing cells stained for b-galactosidase (blue). Scale bar 40µm. (B) Levels of p53 and p21 after induction of extra 
centrosomes (48 hrs). (C) mRNA levels of the different pro-invasive factors 6 days after induction of centrosome 
amplification (Left) or Doxorubicin treatment (Right). (D) Left, Quantification of b-galactosidase positive BF.PLK4 cells 7 
days after induction of centrosome amplification or doxorubicin treatment (100 ng/ml). Right, Cells stained for b-
galactosidase (blue). Scale bar 40µm. (E) Quantification of gH2AX foci in MCF10A cells with extra centrosomes after 
7days. (F) Quantification of gH2AX foci in RPE-1 cells with extra centrosomes after 7days. DoxoR-induced senescent cells 
were used as positive control. L, large nuclei; S, small nuclei. Data as seen in Fig. 5f. (G) Quantification of secreted pro-
invasive factors in senescent cells treated with DoxoR after 6 days. (H) SASP array incubated with CM collected from 
cells with (CM+DOX) and without (CM-DOX) extra centrosomes. DoxoR-induced senescent cells were used as positive 
control. (I) Levels of p53 after p53 siRNA. (J) Levels of p21 after p21 siRNA. (K) Levels of secreted IL-8 in cells depleted of 
p21. (L) Quantification of invasive structures in acini incubated with CM collected from cells depleted of p21. (M) Levels 
of MCAK after MCAK siRNA depletion. (N) Levels of secreted IL-8 in cells depleted of MCAK. (O) Quantification of 
invasive structures in acini incubated with CM collected from cells depleted of MCAK. For all graphics error bars 










Figure S6. Increased ROS levels in cells with extra centrosomes promote secretion and paracrine invasion. Related to 
Figure 6 and Table S1. (A) Quantification of b-galactosidase positive MCF10A.PLK4 cells after 6 days, before and after 48 
hrs treatment with DOX and treated with different doses of H2O2 for 48 hrs. (B) Levels of p53 and p21 in cells with 
(+DOX) and without (-DOX) extra centrosomes treated with H2O2 (100 µM). (C) Ratio of GSH/GSSG in cells after 
induction of extra centrosomes (48 hrs) and H2O2 (100 µM) treatment. (D) Quantification of Ki67 positive cells 2 and 6 
days after induction of centrosome amplification and H2O2 (100 µM) treatment. (E) Cells stained for Ki67 (green) and 
DNA (blue). Scale bar 40µm. (F) Levels of secreted IL-8 in cells with (+DOX) and without (-DOX) extra centrosomes 
treated with H2O2 (100 µM, 48 hrs). (G) Quantification of invasive structures in acini incubated with CM collected from 
cells with (+DOX) and without (-DOX) extra centrosomes treated with H2O2 (100 µM). (H) Levels of secreted MSN after 
NAC treatment (5 mM, 48 hrs). (I) Levels of secreted PAI after NAC treatment (5 mM, 48 hrs). (J) Levels of secreted 
ANGPTL4 after NAC treatment (5 mM, 48 hrs). (K) Levels of secreted GDF-15 after NAC treatment (5 mM, 48 hrs). For all 





 Figure S7. p53-mediated ROS production promotes secretion and paracrine invasion in cells with extra centrosomes. 
Related to Figure 7 and Table S1. (A) Quantification of invasive structures in acini incubated with CM collected from 
cells depleted of p22phox. (B) Cells treated with Antimycin A (35 µM) to increase mitochondrial ROS and stained with 
fluorogenic dye Mitosox (red). MitoTempo was used to inhibit mitochondrial ROS (10 and 15 µM, 48 hrs).  Scale bar 
10µm. (C) Quantification of invasive structures in acini incubated with CM collected from cells with extra centrosomes 
treated with MitoTempo (10 and 15 µM, 48 hrs). (D) Cells were stained with MitoSox (red). Scale bar 10µm. (E) Ratio of 
GSH/GSSG in cells after induction of extra centrosomes (48 hrs) and treated with RAC1 inhibitor (NSC23766, 25 µM, 48 
hrs). (F) Levels of secreted IL-8 in cells with (+DOX) and without (-DOX) extra centrosomes treated with RAC1 inhibitor 
(25 µM, 48 hrs). (G) Schematic representation of the experimental setting to remove RAC1 inhibitor from the CM before 
adding on 3D cultures. (H) Quantification of invasive structures in acini incubated with CM collected from cells treated 
with RAC1 inhibitor (25 µM) before and after removal of the drug (CM filtered). (I) p53 levels in cells with extra 
centrosomes (+DOX) and treated with NAC (5 mM, 48 hrs). (J) Western blot analysis of p53 levels in cells treated with 
Nutlin-3 (5 mM, 48 hrs). (K) Ratio of GSH/GSSG in cells treated with Nutlin-3 (5 mM, 48 hrs). (L) Levels of secreted IL-8 in 
cells treated with Nutlin-3 (5 mM, 48 hrs). (M) Quantification of invasive structures in acini incubated with CM collected 
from cells treated Nutlin-3 (5 mM, 48 hrs). (N) Levels of secreted HMGB1 in cells treated with Nutlin-3 (5 mM, 48 hrs). 
(O) Quantification of invasive structures in acini incubated with CM collected from breast cancer cell lines with low and 
high centrosome amplification. (P) Ratio of GSH/GSSG in HCC1954.PLK4 cells after induction of extra centrosomes 
(+DOX) for 48 hrs. For all graphics error bars represent mean +/- SD from three independent experiments. *P < 0.05, 
**P < 0.01, ***P < 0.001, ns not significant. 
 																									
				
Table S1: Quantification of the percentage of extra centrosomes in the different conditions and cell lines. 
Related to Figures 1, 3, 5, 6, 7, S1, S3, S5, S6 and S7.		
Cell line Treatment(s) % Centrosome 
amplification 
MCF10A.PLK4 n/a* 12 
MCF10A.PLK4 DOX 87 
MCF10A.PLK4-608 DOX 11 
MCF10A.PLK4 after DOX + siRNA ctr  42 
MCF10A.PLK4 after DOX + siRNA SAS-6 18 
HaCat.PLK4 n/a* 21 
HaCaT.PLK4 DOX 73 
MCF10A RO-3306 58 
MCF10A.PLK4 DOX + siRNA IL-8 66 
MCF10A.PLK4 DOX + siRNA ANGPTL4 78 
MCF10A.PLK4 DOX + siRNA GDF15 65 
MCF10A.PLK4 DOX + siRNA PAI 71 
MCF10A.PLK4 DOX + siRNA MSN 61 
MCF10A.PLK4 DOX + siRNA p53 64 
MCF10A.PLK4 DOX + siRNA p21 65 
MCF10A.PLK4 DOX 6 days 39 
MCF10A.PLK4 DOX + NAC 87 
MCF10A.PLK4 DOX + Apocynin 93 
MCF10A Nutlin-3 8 
MCF10A.PLK4 DOX + Rac inhibitor 82 
MCF10A.PLK4 H2O2 8 
MCF10A.PLK4 DOX + H2O2 46 
MCF7. PLk4 n/a* 18 
MCF7. PLk4 DOX 57 
HCC1954.PLK4 n/a* 16 
HCC1954. PLK4 DOX 82 
BF.PLK4 n/a* 1 
BF.PLK4 DOX 44 
RPE.PLK4 n/a* 15 
RPE.PLK4 DOX 80 
   		 	 * n/a: not applicable, no treatment performed 									
Supplementary Table 6: References for all siRNAs used. Related to Figures 3 and S3. 
 
Gene symbol Reference Company 
CXCL8 M-004756-00 Dharmacon 
CCL20 M-007832-01 Dharmacon 
AREG M-017435-00 Dharmacon 
LGALS3 M-010606-02 Dharmacon 
PLAU M-006000-02 Dharmacon 
ANGPTL4 M-007807-02 Dharmacon 
MSLN M-006346-02 Dharmacon 
THBS1 M-019743-01 Dharmacon 
EPCAM M-004568-03 Dharmacon 
DCN M-021491-00 Dharmacon 
GRN M-009285-02 Dharmacon 
SYNE2 D-019259-01 Dharmacon 
CBR3 L-008597-00 Dharmacon 
LDLR L-011073-00 Dharmacon 
PPA2 L-012348-00 Dharmacon 
C1QBP L-011225-01 Dharmacon 
ACTN4 L-011988-00 Dharmacon 
CLIC4 L-013553-00 Dharmacon 
STIP1 L-019802-00 Dharmacon 
PPP1CC L-006827-00 Dharmacon 
LCP1 L-011716-00 Dharmacon 
PDAP1 L-017675-00 Dharmacon 
GSTP1 L-011179-00 Dharmacon 
TPP1 L-005810-00 Dharmacon 
GCSH L-017907-00 Dharmacon 
S100A7 L-011769-02 Dharmacon 
CTSC L-005835-00 Dharmacon 
NAMPT L-004581-00 Dharmacon 
RBM3 L-018969-01 Dharmacon 
PROCR L-017326-00 Dharmacon 
IQGAP1 L-004694-00 Dharmacon 
GDF15 L-019875-00 Dharmacon 
ENO2 L-009777-00 Dharmacon 
AZGP1 L-012567-01 Dharmacon 
SERPINE1 L-019376-01 Dharmacon 
DDT L-012201-01 Dharmacon 
LGMN L-005924-00 Dharmacon 
AXL L-003104-00 Dharmacon 
CEP192 L-032250-01 Dharmacon 
P21 L-003471-00 Dharmacon 
SAS6 L-019156-01 Dharmacon 
P53 L-003329-00 Dharmacon 
CXCR2 L-005647-00 Dharmacon 
CYBA L-011020-02 Dharmacon 
CONTROL 1027310 Qiagen 		
Supplementary Table 7: Primer sequences used in the RT-qPCR. Related to Figures S3, S4 and S5. 	
Gene symbol Primer Forward 5'-3' Primer Reverse 5'-3' 
GAPDH TTAAAAGCAGCCCTGGTGAC CTCTGCTCCTCCTGTTCGAC 
CXCL8 GTTTTTGAAGAGGGCTGAG TTTGCTTGAAGTTTCACTGG 
CCL20 TATATTGTGCGTCTCCTCAG GCTATGTCCAATTCCATTCC 
AREG AAAGAAAGAAAAAGGGAGGC CATTTGCATGTTACTGCTTC 
LGALS3 AGATTTCCAAAGAGGGAATG AAGTGCAAACAATGACTCTC 
PLAU GAAAACCTCATCCTACACAAG ATTCTCTTTTCCAAAGCCAG 
ANGPTL4 AGGCAGAGTGGACTATTTG CCTCCATCTGAGGTCATC 
MSLN GACGTCCTAAAGCATAAACTG TCATCTTGAGGAAGAGGTAG 
THBS1 GTGACTGAAGAGAACAAAGAG CAGCTATCAACAGTCCATTC 
EPCAM GTCTGAGAAGGCTGAGATAAAG CTTCAAAGATGTCTTCGTCC 
DCN TTCACGCATTGATTCTTGTC GCTGATTCTTGGACAGATAAAG 
GRN GACCTGATCCAGAGTAAGTG CATGTCACATTTCACATCCC 
SYNE2 GAGAAGATAGAAGAAGCACTC TCTTATAGGTTTTCTGCTGC 
CBR3 AGTGAGGTGCTAGTTTCCAAGG CTGCACATTCTTGTGGACCC 
LDLR GAGGACAAAGTATTTTGGACAG GTAGGTTTTCAGCCAACAAG 
PPA2 CTGGAAGCTACTCTTAATTGG GCCTTGTTTTTGAATTCTCC 
C1QBP AACATTAACAACAGCATCCC TCATCCTCTGGATAATGACAG 
ACTN4 AGTATGACAAGCTGAGGAAG CTGAAAAGGCATGGTAGAAG 
CLIC4 CCCAGAATCAAATCATGCTG TCAATTTCATCAGGGAGAGG 
STIP1 AACGAGTGTTTTCAGAAAGG TATAACCCTTGATGAAGGTCG 
PPP1CC GAGGTTTATCACCAGATCTTC CAGCCTAAGACATGTTTATCG 
LCP1 AAGCTCTGATTGCTCTTTTG GAAGTTGCCAATTTTGTTGC 
PDAP1 AAGATGACTACCAGCAAAAG CTGCTTCTCAATCTCTTCTC 
GSTP1 GCAAATACATCTCCCTCATC GTCTCAAAAGGCTTCAGTTG 
TPP1 AATAACCTGACCCTAGAGAATG CCACATAGTGATGAAACTCAG 
GCSH TTGTTATGAAGATGGTTGGC TCTAAGTCTTCTATCCACCAC 
S100A7 TTAGTGCCTGTGACAAAAAG GTAGTCTGTGGCTATGTCTC 
CTSC AACAAACTGGCCATGAAC ATAAAGACTCCAGAAGGGAC 
NAMPT CTAATGGCCTTGGGATTAAC TCCAGTGTAACAAAATTCCC 
RBM3 AGTGGCAGGTATTATGACAG TCTGCCATTATAGTCTCTGG 
PROCR CATATGAAGTCTTTGGAGGC CATATGGAAGTCTTTGGAGGC 
IQGAP1 ATGCCTTTGACATCATTGAC TCTAGGTTTCTGGTAGGACTG 
GDF15 CGAAGACTCCAGATTCCG ACTTCTGGCGTGAGTATC 
ENO2 ATGTCCATAGAGAAGATCTGG GACACCTTTGCCTAAGTAAC 
AZGP1 ACAGAAATCACAGTCAATGG TCCAAGTCTACTCAAGACAG 
SERPINE1 ATCCACAGCTGTCATAGTC CACTTGGCCCATGAAAAG 
DDT CCCACTTCTTTGAGTTTCTC ATCTCTCTGGAAGAAGCAG 
LGMN ACTATGATGAGAAGAGGTCC GGTGGAGATTGTTTTGTTTC 
AXL CATGAAACATGGAGACCTAC ATCTCTTGGTACTCAGATACTC 	
